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Microbial Functionality and Safety 
The programme Microbial Functionality and Safety studies the metabolic and enzymatic activities of 
microorganisms. The aim is to improve the health-promoting and organoleptic properties of foods and 
to maintain food safety by destroying food pathogens or increasing shelf life by inhibiting spoilage 
bacteria. 
 
Microbe-mediated gut metabolism 
WCFS aims to identify global and specific relevant metabolic conversions of dietary components by 
the microbiota in the colon, link these to the microbial diversity and its spatial distribution, and study 
their effect on intestinal health, in order to gain insight in and to optimize intestinal functionality by 
addressing the effects of diets on this. Various relatively unrelated disciplines such as microbial 
physiology, human physiology and gastroenterology are combined, and incorporated with 
developments in the biomedical and nanotechnology fields, using a unique combination of stable 
isotopes and ~omics approaches. These include in vitro experiments, interventional strategies in 
human volunteers, and investigational tools, including stable isotope probing, spectroscopic analysis 
and metabolomics, transcriptomics and proteomics. Another part is focused on the development and 
application a sampling device for in situ sampling in the large intestine for the determination of short-
chain fatty acids produced in the colon. The research described here relates to the study of lactose 
metabolism in the colon and its effect on lactose-intolerance and has made use of the various research 
tools describe above. The research was carried out in the Department of Medical Microbiology and 
Center for Medical Biomics, University Medical Center Groningen, University of Groningen, as part 
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BBA   Brucella blood agar 
DAPI   4’, 6-diamidino-2-phenylindole 
DGGE   denaturing gradient gel electrophoresis 
FISH    fluorescent in situ hybridization 
GC   gas chromatography 
IBS   irritable bowel syndrome 
LC-MS/MS  liquid chromatography tandem mass spectrometry 
LDI   lactose digestion index 
OCTT    oro-cecal transit time 
ONPG   ortho-nitrophenyl-ß-D-galactoside 
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SELDI-TOF surface-enhanced laser desorption ionization - time of 
flight 
SSC   6-h symptom score 
SSCP   single strand conformation polymorphism 
TGGE   temperature gradient gel electrophoresis 
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Dairy products provide us with calcium and other valuable nutrients. However, 
they also contain lactose which is maldigested by a large part of the world adult 
population. The mechanisms by which lactose maldigestion causes symptoms of 
lactose intolerance are not fully understood. Studies on the pathophysiology of 
lactose intolerance may aid to design strategies for dietary management of lactose 
intolerance. Limited evidence suggests that colonic metabolism of lactose, in 
addition to the small-intestinal lactase activity and transit, might be involved in the 
development of symptoms.  
      Data on digestion and transit of lactose in the small intestine are needed when 
clarifying possible involvement of the colon in lactose intolerance. The oro-cecal 
transit time (OCTT) and the degree of lactose digestion were determined using 
newly developed stable isotope-based methods. Lactose triggered faster oro-cecal 
transit in lactose maldigesters, but not in digesters. This could not be explained by 
intestinal distention resulting from the osmotic load posed by maldigested lactose, 
and thus suggested a direct effect of lactose on intrinsic factors regulating intestinal 
motility. The lactose tolerant and intolerant subjects did not differ in OCTT or the 
degree of lactose digestion, which indicates the involvement of other 
pathophysiological mechanisms in lactose intolerance. We hypothesize that colonic 
metabolism of lactose is one of these mechanisms. 
      Two in vitro studies were carried out to investigate the possible role of 
fermentation of lactose by the colonic microbiota in lactose intolerance. During 
colonic fermentation, lactose is first hydrolyzed to glucose and galactose, catalyzed 
by ß-galactosidase. Glucose and galactose are subsequently fermented, leading to 
production of short-chain fatty acids (SCFA) and gases. When incubated with 
lactose in vitro, fecal bacteria from the lactose intolerant subjects produced more 
lactate, acetate, propionate and butyrate at a higher rate than the tolerant subjects. 
The results suggest that a faster and higher production of microbial intermediate 
and end metabolites during colonic fermentation of lactose, may be related to the 









lactose hydrolysis are involved. Bacterial ß-galactosidase activity is abundant in 
the colon as more than 80% of the cultured fecal bacteria were found to possess 
this activity. The lactose tolerant and intolerant subjects did not differ in the 
relative amount or composition of the fecal bacteria with ß-galactosidase activity, 
ß-galactosidase activity in feces, or hydrolysis of lactose in vitro. We hypothesize 
that accumulation of SCFA and/or other metabolites resulting from fast 
fermentation of lactose in combination with insufficient removal plays a role in 
onset of symptoms. 
      As the in vitro study indicates that colonic fermentation may be involved in 
lactose intolerance, we continued to: (i) investigate whether the colonic microbiota 
could be modulated by dietary supplementation for the purpose of alleviating 
symptoms; (ii) explore proteomics techniques to study metabolic pathways of 
lactose fermentation by the colonic microbiota; (iii) design an in vivo study to 
verify the observations of the in vitro study. 
      A 2-w supplementation of probiotic bacteria (Bifidobacterium longum) and a 
yogurt enriched with Bifidobacterium animalis modified the amount and probably 
the metabolic activities of the colonic microbiota of lactose intolerance subjects. 
Lactose-induced symptoms decreased after the supplementation. The 
supplementation did not increase the endogenous lactase activity in the small 
intestine. Results indicate that the changes in the colonic microbiota may play a 
role in alleviation of intolerant symptoms. 
      Bifidobacteria were used as a model system to explore proteomic methodology 
which can be used to study metabolic pathways of lactose by the colonic 
microbiota. Differential protein expression profiles of Bifidobacterium grown on 
lactose, glucose or galactose were obtained by using surface-enhanced laser 
desorption ionization - time of flight MS and sodium dodecyl sulfate 
polyacrylamide gel electrophoresis. LC-MS/MS was used for identification of 
proteins . 
      An in vivo study is proposed to verify our observations in the in vitro study that 









isotope-labeled lactose will be delivered to the cecum via a catheter and kinetics of 
13C-acetate in the peripheral blood will be monitored. 
     The results presented in this dissertation contribute to the understanding of the 
colonic metabolism of lactose in the context of lactose intolerance. Colonic 
fermentation of lactose may play a role in lactose intolerance. Dietary modulation 

















Dairy products are important sources of many nutrients including calcium, high-
quality protein, potassium and riboflavin. It is not clear why there has to be a 
special carbohydrate, lactose, in milk. Lactose is the principal carbohydrate in 
human and animal milk. Human milk contains an average of 7% lactose, while 
whole cow’s milk contains 4.8%. During infancy, all human and mammals possess 
high levels of the enzyme lactase in their small intestine, which enables digestion 
of lactose. After weaning, a large part (~75%) (1) of the world population 
undergoes a genetically-determined decline in lactase activity, which can lead to 
maldigestion of lactose. Lactose maldigestion can, but not necessarily, cause 
unpleasant gastrointestinal symptoms, termed lactose intolerance. 
      Lactose intolerance is one of the factors that may influence milk consumption. 
Studies suggest that lactose maldigesters consume less milk than digesters, 
possibly as a result of experiences of unpleasant symptoms after ingestion of 
lactose-containing dairy products (2-5). Persons who consume less milk as a result 
of lactose intolerance generally have lower intake of calcium and other nutrients 
supplied by milk. Several studies have indicated an increased frequency of lactose 
maldigestion in patients with osteoporosis (6,7). A connection between lactose 
maldigestion and decreased absorption of calcium has not been proven. The reason 
for the high incidence of lactase deficiency in people with osteoporosis could be a 
lower calcium intake in this group because of lactose intolerance (2). 
The causes of the symptoms of lactose intolerance are not well understood. 
Several factors are considered to be involved in the occurrence of symptoms, 
including the amount of lactose ingested, lactase activity, intestinal transit time, 
and other factors such as visceral sensitivity or bowel motor abnormalities (8). 
Recently the possible involvement of colonic factors has been suggested (9). 
However, little knowledge is available concerning the role of the colon in lactose 
intolerance. Understanding the pathophysiology of lactose intolerance will aid to 
design strategies for dietary management of lactose intolerance. The dietary 
management of lactose intolerance would help lactose intolerant subjects to 











1.  Lactose digestion and maldigestion, and lactose intolerance 
   
1.1  Lactose metabolism in normal-lactasia 
Lactose is a disaccharide composed of the two monosaccharides, glucose and 
galactose. To be absorbed, lactose needs to be hydrolyzed into glucose and 
galactose. The hydrolysis is catalyzed by lactase, lactase-phloritzin hydrolase (EC 
3.2.1.23/26), a ß-galactosidase. Lactase is located in the brush border of the 
intestinal epithelium and has its highest activity in the jejunum. Of all the dietary 
sugars, lactose is hydrolyzed the most slowly. Hydrolysis of lactose proceeds at 
approximately half the rate of sucrose hydrolysis (10). After hydrolysis, glucose 
and galactose are absorbed from the intestine by active transport. Galactose is 
metabolized mainly in the liver via the Leloir pathway to glucose. This pathway is 
very efficient, almost half of the galactose administered enters the body glucose 
pool within 30 min (11,12). 
 
1.2  Hypolactasia, lactose maldigestion and lactose intolerance 
Hypolactasia refers to a very low activity of lactase in the jejunal mucosa (13). It 
can be primary (genetic) or secondary. Primary hypolactasia is genetically 
determined and occurs soon after weaning in almost all animals and in many 
human ethnic groups. The lactase activity drops to about one tenth or less of the 
suckling level. Primary hypolactasis is also referred to as adult-type hypolactasia 
or lactase non-persistence. Secondary hypolactasia results from damages to the 
intestinal mucosa which can be caused by intestinal resections, gastrectomy or 
some intestinal disease. Congenital lactase deficiency is extremely rare. Lactase 
activity is decreased or absent at birth, and this deficiency persists throughout life 
(8,10,14). 
Hypolactasia leads to lactose maldigestion, which in turn can cause lactose 
intolerance, but not in all cases. Lactose intolerance refers to the gastrointestinal 
symptoms associated with the incomplete digestion of lactose (1). The symptoms 
include abdominal pain, cramps, flatulence, nausea, or diarrhea. Lactose 
maldigestion correlates poorly with symptoms of lactose intolerance (15). This is 
supported by the following observations (15): (i) not all lactose maldigesters will 
  
16 
develop symptoms after lactose ingestion, some maldigesters can be lactose 
tolerant (9); (ii) the decline of lactase activity starts much earlier than does the 
manifestation of clinical symptoms (16); (iii) not all lactose intolerant subjects are 
symptom-free after ingestion of lactose-free diets. Therefore, lactose intolerance 
can be referred to as symptomatic lactose maldigestion. In the literature the term 
“lactose intolerance” is sometimes wrongly used to mean lactose maldigestion (13). 
 
1.3  Prevalence and genetics of adult-type hypolactasia 
In general, hypolactasia is more common in populations outside Europe than inside 
Europe. Prevalence of hypolactasia in European countries around the North Sea is 
as low as less than 10% and rises in Central and Southern Europe to 70% in Sicily. 
The highest prevalences of hypolactasia have been reported from the countries in 
Far East Asia, a prevalence of 100% was found in Northern Thailand and Vietnam. 
The prevalences in different Chinese groups range from 43 to 92%. In the United 
States, the prevalences are 6% to 19% in whites, 53% in Mexican Americans and 
80% in African Americans. Prevalences ranging from 13% to 90% were reported 
for South Africa (17). 
      The inter-individual differences in lactase activity are due to a genetic 
polymorphism. The lactase non-persistent people are homozygous for an autosomal 
recessive allele, while lactase persistent people are heterozygous or homozygous 
for a dominant allele LCT*P. Lactase persistence behaves as a dominant trait 
because half the levels of the normal lactase activity are sufficient to show 
significant digestion of lactose. The different lactase phenotypes are controlled by a 
polymorphic element cis-acting to the lactase gene. A putative causal nucleotide 
change has been identified and occurs on the background of a very extended 
haplotype that is frequent in Northern Europeans, where lactase persistence is 
frequent. This single nucleotide polymorphism is located 14 kb upstream from the 
start of transcription of lactase in an intron of the adjacent gene MCM6. This 
change does not, however, explain all the variation in lactase expression. There is 
no evidence for adaptive alteration in lactase expression (18). Genotyping of single 
nucleotide polymorphism C/T(-13910) (19,20)and c.1993+327C (21) has been 









reported peroral gene therapy of lactose intolerance using an adeno-associated 
virus vector (22). 
 
1.4  Factors that may influence lactose digestion and lactose intolerance 
In persons with hypolactasia, besides the lactase activity in the small intestine, 
other factors may influence lactose digestion and occurrence of lactose intolerance 
as well. These factors include gastrointestinal transit, the amount of lactose 
ingested, etc. These are discussed in short below. 
 
1.4.1  Gastrointestinal transit 
Prolonged gastric emptying and intestinal transit enable longer contact between the 
residual brush-border lactase and lactose, and thus may improve lactose digestion 
and alleviate symptoms. This can be the mechanism behind the observations in 
many studies which show pasteurized yogurt improves lactose digestion (23-25) 
and improved lactose tolerance after ingestion of chocolate milk (26,27) and full-
fat milk compared with skimmed milk or ingestion of milk with a meal instead of 
milk on its own (28,29). Several studies show that a longer oro-cecal transit time 
(OCTT) contributes to less symptoms in lactose maldigesters (9,30-32). However, 
Roggero et al. did not observe differences in the small bowel transit times between 
symptomatic and asymptomatic malabsorbing subjects (33). 
 
1.4.2  Amount of lactose ingested 
Most of the lactose maldigesters can ingest a certain amount of lactose without 
developing any symptoms. The term lactose intolerance should be used when 
referring to the symptomatic response to a defined amount of lactose load. A small 
amount of lactose (6-7 g) does not induce symptoms of lactose intolerance (34,35). 
The amount of lactose (12 g) in one cup of milk (240 ml) can be tolerated by most 
maldigesters (36-38). Ingestion of 50 g of lactose causes symptoms in 80% to 
100% of lactose maldigesters (39,40). Even after ingestion of a large amount of 
lactose, a small percentage of maldigesters remained symptom-free (14). The 




1.4.3  Gender 
Men and women do not differ in the prevalence of hypolactasia (41,42). However, 
women seem to report higher symptom scores than men, while it is not clear 
whether there is difference in hydrogen production between the two genders (42-
44). 
 
1.4.4  Pregnancy 
Villar et al. demonstrated that 44% of women who maldigested 360 ml of milk (18 
g of lactose) before the 15th week of gestation, were able to digest that amount of 
lactose by the end of their pregnancy (45). The mechanism is unknown. Some 
researchers hypothesize that slower intestinal transit during pregnancy improves 
digestion of lactose (46,47). 
 
1.4.5  Age 
The age at which manifestation of hypolactasia occurs is generally earlier in a 
population with a high prevalence of hypolactasia (more than 80%) than in a 
population with low prevalence. The former starts at the age of 2 to 7 y and the 
latter starts after 4-5 y and continues until 20 y (17). 
In animal studies, lactase activity was found to decrease with age (48,49). But 
lactase activity in human duodenal biopsies did not change significantly with age 
(50,51). Gastric emptying was prolonged in the elderly (52-54). The small bowel 
transit time, OCTT or whole gut transit time did not change with age (52-55). 
However, Pilotto et al. found that OCTT increased in healthy aging (56). There 
might be differences in hydrogen production after ingestion of lactose, but the 
findings are not consistent (41,42,57,58). Results of the experience of symptoms of 
lactose intolerance according to age are also contradictory (58,59). 
 
1.4.6  Subjective factors 
Lactose maldigestion can be diagnosed by objective testing. The classification of 
lactose intolerance, however, is based on the individual’s perception of symptoms 
except when diarrhea is prominent. Symptom reporting by individuals seems to be 









digesters or maldigesters, reported intolerance symptoms to whatever placebos 
used in double-blinded studies (38,60-62). Familiarization with the test procedure 
also influences symptom recording (63). These observations suggest the possible 
involvement of psychological factors and that some gastrointestinal complaints are 
often mistakenly attributed to the consumption of lactose or milk. Well-designed 
and double-blinded clinical trials are recommended for the studies of lactose 
intolerance. 
 
1.4.7 Functional gastrointestinal disorders 
Functional gastrointestinal disorders are a variable combination of chronic or 
recurrent gastrointestinal symptoms not explained by structural or biochemical 
abnormalities. The symptoms of functional bowel disorders (for instance, irritable 
bowel syndrome (IBS)) and dysmotility-type dyspepsia resemble those of lactose 
intolerance (8). In several studies, a relation between lactose intolerance and IBS 
was observed (64-66), whereas data from other studies do not support this 
observation (67,68). Visceral hypersensitivity and hyperalgesia (69) and small 
bowel dysmotility (70) have been documented in IBS. Motor-sensory interactions 
is also suggested for IBS, i.e. altered motility potentiates the sensory response to 
relatively physiological levels of intraluminal stimulation (71). Hammer et al. (72) 
investigated the role of symptom perception in lactose intolerance and suggested 
that subjective symptoms of lactose intolerance are not due to the amount of 
malabsorbed lactose or to the volume or rate of gas accumulation per se, but are 
related to increased perception of gas. 
 
1.4.8   Colonic processing of lactose 









2. Colonic processing of lactose and lactose intolerance 
 
2.1  Lactose metabolism in hypolactasia 
When the lactase activity in the small intestine is not enough to hydrolyze all the 
ingested lactose, maldigested lactose enters the colon where it is fermented by the 
colonic microbiota. Lactose is first hydrolyzed by bacterial ß-galactosidase into 
glucose and galactose. Galactose will be converted into glucose via the Leloir 
pathway, glucose will be subsequently fermented (73,74). Short-chain fatty acids 
(SCFA) (acetate, propionate and butyrate) and gases (CO2, H2 and CH4) are the 
end-metabolites of bacterial fermentation of lactose (Figure 1). Some intermediates, 
for instance, lactate, ethanol and succinate, are produced and then further 
metabolized to SCFA. SCFA and gases are thought to be readily absorbed from the 
colon (10,11,75). Acetate is the principal SCFA produced (~50%). It passes 
through the liver and is finally metabolized in the peripheral tissues (76). Butyrate 
serves as an important fuel for colonocytes (77). Absorbed propionate and butyrate 
are metabolized in the liver (76). Gases are partially absorbed from the intestine 
into the blood and partially excreted through the lung and partially excreted as 
flatus or used for synthesis of other metabolites (78,79). 
 
2.2  Colonic processing of lactose might play a role in lactose intolerance 
Colonic fermentation of lactose might be involved in lactose intolerance, which is 
supported by the following observations: 
(i)   the colonic microbiota is involved in metabolism of maldigested lactose 
(11)(see 2.1). 
(ii)  Subjects with similar OCTT and degree of lactose digestion in the small 
intestine developed symptoms of different severity (9). 
(iii)  Adaptation of long-term lactose ingestion may be related to adaptation of the 
colonic microbiota and colonic function. Continuous lactose consumption 
reduces breath hydrogen excretion, increases fecal ß-galactosidase activity 
and improves lactose intolerant symptoms (63,80,81). Adaptive changes in 









    
 
Figure 1. Fermentation of lactose by the colonic microbiota. (Modified based on Reilly & 




microbiota  (84),   less   bacterial     hydrogen     production  (85),  decreased 
perception of symptoms by the subjects, and placebo effects have been 
suggested as explanations for these observations (15). 
      However, few studies have been directed to investigate the possible role of 
colonic fermentation of lactose in lactose intolerance. 
 
2.3  Aspects in colonic processing of lactose that may influence lactose 
intolerance 
The following aspects of the colon might affect the symptoms of lactose 
intolerance (8,86): (i) the composition and metabolic activities of the colonic 
microbiota; (ii) the ability of the colon to remove fermentation metabolites; (iii) 
visceral sensitivity (symptom perception) (72). 
 
2.3.1  The balance between production and removal of the fermentation 
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Whether colonic fermentation of maldigested lactose would influence the 
occurrence of lactose intolerance, either aggravate or alleviate it, depends on the 
balance between the ability of the colonic microbiota to ferment lactose and the 
ability of the colon to remove the fermentation metabolites. A low lactose-
fermenting capacity of the colonic microbiota, which leads to inefficient removal 
of maldigested lactose (and/or its intermediate fermentation metabolites), or a low 
absorption capacity of the colon which leads to inefficient removal of fermentation 
metabolites, may contribute to development of symptoms. When lactose is 
converted to SCFA by fermentation, the osmotic load is increased about 8-fold, 
which makes the efficiency of the colon to absorb these fermentation metabolites 
an important determinant for the outcome of the osmotic load caused by 
malabsorbed lactose (86). 
 
2.3.2   Removal of SCFA in the colon 
SCFA produced by bacterial fermentation are removed from the colon through the 
following routes: 1) absorption by the colon; 2) utilization by the colonocytes 
(butyrate); 3) excretion in feces; 4) incorporation into the bacterial biomass: it has 
been suggested that ~40% of carbon atoms produced from the fermented hexosyl 
moiety may be used for bacterial growth (87). 
SCFA are presumably absorbed by both ionic and non-ionic diffusion. It is 
generally believed that the colon has a high capacity to absorb SCFA, with the 
absorption rate being 6.1-12.6 µmol/(cm2.d) (88-91). SCFA absorption stimulates 
sodium and chloride absorption and bicarbonate secretion (92,93). There are 
differences among segments in colonic permeability for the three major SCFA. 
Acetate is absorbed at the highest rate in the cecum and proximal colon, and 
butyrate in the distal colon; propionate is absorbed at a similar rate in the proximal 
and distal colon (94). Lactate is an intermediary organic acid in the bacterial 
fermentation of carbohydrates and is further converted to SCFA and as a result, it 
is rarely present in large amounts in feces (89,95,96). 
Although the colon is believed to possess a high capacity to absorb SCFA, it 









short period in situ all the SCFA and lactate produced from rapid fermentation of 
some carbohydrates, for instance, lactose. 
 
2.4  Colonic metabolism of lactose and the pathophysiology of lactose 
intolerance 
The mechanisms by which lactose maldigestion causes symptoms of lactose 
intolerance are not fully understood yet. Generally speaking, the osmotic load of 
maldigested lactose increases secretion of fluid and electrolytes to the lumen, 
causing dilatation of the intestine. Intestinal dilatation induces acceleration of small 
intestinal transit (31,97), which further aggravates maldigestion of lactose (8). 
Distention caused by the additional water content in the lumen and the gaseous 
products of fermentation, plus the possible effects of the SCFA on colonic motility, 
lead to the characteristic signs and symptoms of lactose intolerance (10). In some 
studies, the correlation between colonic fermentation and loose stool or diarrhea 
and the correlation between bacterial production of gas and abdominal distention, 
cramps and flatulence, were investigated. 
 
2.4.1   Colonic fermentation and loose stool or diarrhea 
Loose stool or diarrhea are generally believed to be results of the osmotic effect 
exerted by maldigested lactose. The role of colonic fermentation of lactose in 
diarrhea in lactose intolerance needs further clarification. Disordered peristalsis and 
water absorption in the colon caused by products of lactose fermentation may be 
involved in development of loose stool or diarrhea (98,99). However, as it is 
generally believed that SCFA are rapidly absorbed from the colon, colonic 
fermentation is suggested to help to reduce osmotic load in the colon 
(10,92,93,100). Hammer et al. (101) investigated the influence of colonic 
metabolism of malabsorbed carbohydrates on diarrhea by comparing diarrhea 
induced by nonabsorbable, non-fermentable polyethylene glycol and by 
nonabsorbable, fermentable lactulose. The results suggest that bacterial metabolism 
affects diarrhea and the effect is dose-dependent. When the amount of malabsorbed 
lactulose was within the metabolic capacity of the colonic microbiota (45 g/d), the 










and subsequent absorption of SCFA. Thus, diarrhea was attenuated. The mild 
diarrhea observed after 45 g of lactulose was probably mainly due to unabsorbed 
SCFA. When the amount of malabsorbed lactulose was beyond the metabolic 
capacity of the colonic microbiota (>95 g/d), unfermented lactulose retains water in 
the colon lumen and thus retards absorption of SCFA. The diarrhea was aggravated 
and was due to unmetabolized lactulose and unabsorbed SCFA. However, a study 
by Holtug et al. (102) does not fully support this conclusion. High intake of 
lactulose caused a decrease in fecal pH to < 5, which inhibited colonic fermentation, 
before the appearance of carbohydrate in feces. The osmotic drive due to the 
unfermented carbohydrate, instead of SCFA, is interpreted to be the cause of 
diarrhea. Nevertheless, this interpretation was only supported by results from half 
the subjects in the study in whom diarrhea appeared suddenly and after appearance 
of carbohydrate in feces. In the other half of the subjects, diarrhea developed 
gradually and before appearance of carbohydrate in feces. Moreover, the drop of 
fecal pH was likely the result of incomplete removal of fermentation products. 
Clausen et al. (103) compared diarrhea induced by idolax and lactulose which are 
fermentable but of different osmolarity. They concluded that difference in colonic 
fermentation seem to play a determining role in the interindividual variability in 
diarrhea associated with carbohydrate malabsorption. A high fermentation capacity 
may help to abolish the laxative effect caused by the malabsorbed carbohydrates 
(103). 
Theoretically, the outcome of the colonic osmolar load of malabsorbed lactose is 
determined by the relation between the ability of the fecal microbiota to ferment 
lactose and the efficiency with which the colonic mucosa absorbs these 
fermentation products (86). 
 
2.4.2  Bacterial production of gas and abdominal distention, cramps and flatulence 
Gas produced from bacterial fermentation of lactose is probably the cause of 
abdominal bloating, flatulence and borborygmi and might be involved in 
development of distention and cramps. 
Abdominal distention and cramps were suggested to originate from the small 









from the colon as lactulose either ingested orally or introduced directly to the colon 
caused similar symptoms (104). 
Theoretically, colonic fermentation of 50 g of lactose will produce ~17 L of 
hydrogen (105). If allowed to accumulate, this volume would have major 
implications for intestinal distention and gas problems. However, most of the gas is 
consumed by other intestinal bacteria. Hammer et al. did not observe difference in 
volume or rate of colonic hydrogen accumulation in lactose malabsobers with or 
without symptoms after ingestion of 50 g of lactose. They suggested that symptoms 
were related to increased perception of gas (72). Similar results were obtained in 
studies on functional bowel disorders. Lasser et al. concluded that the functional 
abdominal symptoms may result from disordered intestinal motility in combination 
with an abnormal pain response to gut distention other than from increased gas 
accumulation in the intestine (106). In IBS patients, increased intestinal gas content 
results from impaired gas transit instead of from increased gas production. Gas 
content and transit appear to conspire with the motor and sensory responses of the 
gut and thus produce gas-related symptoms, both in normal individuals and 
especially in IBS patients (107). 
Intestinal gas tolerance is normally high as expeditious gas transit and 
evacuation prevent gas accumulation. When gas transit and/or evacuation is 
impaired, gas retention occurs, which causes abdominal symptoms and distention 
(108). The perception of intestinal gas accumulation depends on the mechanism of 
retention. Obstructed evacuation increased symptom perception, whereas gas 
retention caused by defective propulsion was virtually unperceived (109). 
Intraluminal gas distribution influences symptom perception. A similar 
magnitude of gas retention produced significantly more abdominal symptoms with 
jejunal or duodenal compared with rectal infusion (110,111). 
 
 
3.  The colonic microbiota 
 
The human colon is the home for a complex consortium of microorganisms 










referred to as the colonic microbiota. The total number of bacteria in the human gut 
is ~1014, which outnumbers the total number of body cells by ~10-20 times. The 
human gut microbiota plays an important role in human health and disease through 
its involvement in nutrition, pathogenesis and immunology of the host (112). 
 
3.1  The composition of the colonic microbiota  
The number of microbial species present in the human colon is not clear yet. It has 
been estimated statistically that 400 to 500 species are present (113). Sequence 
analysis of 16S ribosomal RNA (rRNA) and 16S rDNA revealed that the majority 
of intestinal microbiota clustered within 3 bacterial groups: Bacteroides, 
Clostridium coccoides and Clostridium leptum (113,114). 
      The conventional method to quantify colonic bacteria is by cultivation. 
Culturing techniques have long been suggested to be inadequate to quantify 
intestinal bacteria as firstly, a large fraction of the microbiota cannot be cultured 
yet (113,115) and secondly, specific culturing media may not be truly specific. 
Therefore, recent years have seen a fast development in molecular techniques 
(culture independent) to determine colonic bacteria. These molecular approaches 
are based on the sequence diversity of the 16S rRNA. Frequently applied culture 
independent approaches include sequencing of clone libraries of 16S rRNA 
encoding genes, fingerprinting of 16S rRNA encoding genes (for instance, 
denaturing gradient gel electrophoresis (DGGE)), fluorescent in situ hybridization 
(FISH), diversity microarrays, etc. Zoetendal et al. summarized the currently used 
molecular techniques to study complex microbial ecosystems (116) (Table 1).  
      For enumeration of the colonic microbiota, FISH is an extensively used culture-
independent technique (117-119). Fecal microbiota are suggested to be able to 
reflect the colonic microbiota (120-122). Harmsen et al. (123) and He et al. (124) 
investigated the composition of fecal microbiota of adults and the elderly (Table 2). 
In adults, Bacteroides/Prevotella, the Eubacterium rectale/Clostridium group and 
the Atopobium group are the most predominant groups in feces. Compared to 
adults, the percentages of some bacterial groups to total microbiota in the elderly 
were higher, i.e. the Ruminococcus group, Bifidobacterium, the Eubacterium 









percentages of other groups, such as Bacteroides/ Prevotella and the Eubacteriu. 
rectale/Clostridium group, were lower in the elderly. As analyzed with FISH, in 
breast-fed newborn infants, bifidobacteria dominate the colonic microbiota, with 
lactobacilli and streptococci as the main minor groups. In formula-fed infants, 
Bacteroides and bifidobacteria are equally predominant, with staphylococci, 
Escherichia coli, and clostridia as the minor groups (125). Lay et al. (126) studied 
the composition of the fecal microbiota of subjects from five Northern European 
countries with FISH combined with flow cytometry. Clostridium coccoides and 
Clostridium leptum were the dominant groups (28.0% and 25.2%), followed by 
Bacteroides (8.5%). There were no significant differences in the bacterial 
composition with respect to geographic origin, age, or gender.  
 
3.2  Studying the metabolic activities of the colonic microbiota in vitro and in 
vivo 
Colonic bacteria ferment carbohydrates and proteins and produce SCFA (mainly 
acetate, propionate and butyrate) and gases (H2, CO2, CH4). Most colonic bacteria 
first ferment carbohydrates and switch to protein fermentation when carbohydrates 
are used up (127). Carbohydrates and proteins available for microbial fermentation 
are mostly of dietary origin but can also be host-derived, for instance, mucin and 
pancreatic enzymes (128). Carbohydrate fermentation takes place in the proximal 
part of the colon and protein fermentation occurs in the distal colon (129). In vitro 
and in vivo models are used to study the metabolic activities of the colonic 
microbiota. 
 
3.2.1  In vitro 
As sampling of the colonic content is difficult, in vitro models are often used in 
studies on metabolic activities of the colonic microbiota. Fecal or cecal materials 
are incubated in vitro in buffer or culture medium under anaerobic atmosphere. 
There are two types of in vitro systems: 
(i) static system: the culture system is sealed, there is no exchange of fluid 










conditions in the cultures are constantly changing, for instance, pH and 
bacterial population. 
(ii) continuous system: there is addition of fresh growth medium and removal 
of used culture continuously or at intervals. The continuous system 
simulates the in vivo gut to a certain degree. However, it ignores host input, 








Table 1.  A summary of current techniques used to study complex microbial ecosystems 
 
Methods Uses Limitations 
Cultivation Isolation; "the ideal" Not representative; slow & 
laborious 
16S rDNA sequencing Phylogenetic identification Laborious; subject to PCR bias 
DGGE/TGGE/TTGE Monitoring of community/population 
shifts; rapid comparative analysis 
Subject to PCR bias; Semi-
quantitative; identification 
requires clone library 
T-RFLP Monitoring of community shifts; rapid 
comparative analysis; very sensitive; 
potential for high throughput 
Subject to PCR bias; semi-
quantitative; identification 
requires clone library 
SSCP Monitoring of community/population 
shifts; rapid comparative analysis 
Subject to PCR bias; semi-
quantitative; identification 
requires clone library 
FISH Detection; enumeration; comparative 
analysis possible with automation 
Requires sequence information; 
laborious at species level 
Dot-blot hybridization Detection; estimates relative abundance Requires sequence information; 
laborious at species level 
Quantitative PCR Detection; estimates relative abundance Laborious 




Monitoring of community shifts; rapid 
comparative analysis 
Identification requires 
additional 16S rRNA-based 
approaches 
 









Table 2. Composition of fecal microbiota of adults (n=11) and elderly people (n=15) 
determined by FISH or DAPI staining 1 
 
Bacteroides/Prevotella Bac303  1.0 ± 0.5                27.7   0.5 ± 0.9               10.3 
E.rectale/C.coccoides group Erec482  0.8 ± 0.4                22.7   0.2 ± 0.2                 3.8 
Atopobium group Ato291  0.4 ± 0.3                11.9   0.4 ± 0.5                 7.9 
 
1
 Values are means ± SD or %. 
2
 per g feces, wet weight 
3Percentage of Bacteria (Eub338). 
     -: No data were reported 




3.2.2   In vivo 
Studies on metabolic activities of the colonic microbiota are carried out in 
experimental animals and human volunteers. Laboratory animals with conventional 
gut microbiota, particularly rodents (131) and pigs (132,133), have been used for 
studies of the gut microbiota. However, differences exist in the composition of the 
Adults (20-55 yr) 
 
Elderly (>75yr) Bacterial groups Stain or probes 
Cells (1010)2  % bacteria3  Cells (1010) 2    bacteria3 
Bacteria Eub338 3.5 ± 1.6              100  5.1 ± 2.6             100 
Eubacterium low G+C2 Elgc01 0.4 ± 0.3                10.8  - 
Ruminococcus group Rbro729/Ffla73
0 
0.4 ± 0.5                10.3  0.6 ± 0.4               12.5 
Fecalibacterium Fprau645 -  0.2 ± 0.2                 4.9 
Bifidobacterium Bif164 0.2 ± 0.1                  4.8  0.3 ± 0.6                 6.0 
E. cylindroides group Ecyl387 0.04 ± 0.07              1.4  0.1 ± 0.2                 3.2 
Phascolarctobacterium group Phasco741 0.02 ± 0.03              0.6  0.02 ± 0.05             0.5 
Enterobacteriaceae Ecoli1531 0.006 ± 0.01            0.2  0.2 ± 0.6                 2.2 
Streptococcus/Lactococcus Strc493 -  0.02 ± 0.03             0.4 
Veillonella Veil223 0.002 ± 0.004          0.08  0.001± 0.001          0.0 
Lactobacillus/Enterococcus Lab158 0.0004 ± 0.0009      0.01  0.01± 0.02              0.3 
C.histolyticum/lituseburense 
group 










colonic microbita between animals and man. To circumvent this problem, human 
microbiota-associated rodents were explored (134-136). 
      Studies with human subjects are rare, considering difficulties in quantitative 
delivery of substrates to the colon and sampling in situ in the colon. Techniques 
using stable isotopes provide alternative approaches to study colonic metabolism in 
vivo (137-139). For studying colonic fermentation of a certain substrate in vivo 
using stable isotopes, a labeled tracer is infused at a constant and known rate until a 
new steady-state is reached. Then the substrate of interest is administered, orally or 
delivered with a certain device.  Blood samples are collected at regular intervals. 
From the isotopic enrichment in blood at a steady-state, the production or 
elimination rates of metabolites of the substrate of interest can be calculated based 
on a principle of isotope-dilution. Furthermore, colon-delivery catheters (104) and 
capsules (140) can be considered for quantitative delivery of substrates of interests 
to the colon. 
 
3.3  Proteomics and metagenomics in studying metabolism and structure of 
the colonic microbiota 
Proteins are important for cell structure and function. Whereas their basic 
biological functions are encoded by genes, the structure and function of proteins 
are also regulated by post-translational modifications. Proteomics is the large-scale 
study of proteins, usually by biochemical methods. Proteomic techniques have 
been applied to explore bacterial proteomes. New methodologies are being 
developed (141,142). In proteomic studies of microorganisms, two main 
approaches can be envisaged. The first one is to establish a systematic cartography 
of a bacterium in a given state. The second one is a differential approach, 
consisting of comparing protein patterns of a given strain, submitted to different 
environmental conditions (143). A few proteomic studies have been devoted to 
intestinal bacteria. Recently, proteomic profiles of Bifidobacterium infantis (144) 
and B. longum (145) were described. Bifidobacterium is one of the predominant 










Recently, metagenomics has emerged as a powerful tool to study the intestinal 
microbiota. Metagenomics has been defined as the science of biological diversity. 
It combines the use of molecular biology and genetics to identify and characterize 
genetic material from complex microbial environments. A full metagenomic 
approach is a comprehensive study of nucleotide sequence, structure, regulation, 
and function, providing a picture of the dynamics of complex microbial 
communities. The combination of metagenomics and subsequent quantification of 
each identified species using molecular techniques allows the relatively rapid 
analysis of a whole bacterial population, including uncultured microorganisms 
(147,148). With metagenomic analysis, Gill et al. defined the gene content and 
encoded functional attributes of the gut microbiome in healthy humans (149). 
Manichanh et al. observed reduced diversity of fecal microbiota in patients with 
Crohn’s disease with a metagenomic approach (150). 
 
3.4  Modulating the colonic microbiota with pre-, pro-, and synbiotics to 
alleviate  lactose intolerance 
The human gut microbiota influences health and well-being through its 
involvement in nutrition, pathogenesis and immunology of the host (112). The 
targeted use of dietary supplementation of e. g. pre-, pro- and synbiotics, may 
modulate the composition and some metabolic activities of the colonic microbiota 
such that certain health-benefits or remedial effects can be achieved (151,152). 
 
3.4.1   Probiotics 
Probiotics are defined as “a preparation of or a product containing viable, defined 
microorganisms in sufficient numbers, which alter the microflora (by implantation 
or colonization) in a compartment of the host and by that exert beneficial health 
effects in this host” (153). In several reviews (15,154,155), probiotics are regarded 
to be able to improve lactose digestion and eliminate symptoms of intolerance. The 
mechanisms by which probiotics exert their effects are not clear, but may involve 
modifying gut pH, providing bacterial ß-galactosidase, positive effects on intestinal 










 (156), it is concluded that probiotic supplementation in general did not alleviate 
the symptoms and signs of lactose intolerance in adults. 
 
3.4.2   Prebiotics 
Prebiotics are non-digestible food ingredients that beneficially affect the host by 
selectively stimulating the growth and/or activity of one or a limited number of 
bacterial species already resident in the colon, and thus attempt to improve host 
health (112). The traditional targets for prebiotics are Bifidobacterium spp. and 
Lactobacillus spp. Recently, Palframan et al. (157) devised a prebiotic index for in 
vitro comparison of the prebiotic effect of different oligosaccharides. The prebiotic 
index takes into account the levels of bifidobacteria, lactobacilli, clostridia and 
bacteroides. Most prebiotic research has been done with (2–1) fructans, but 
prebiotic potential has also been shown for galacto-oligosaccharides, xylo-
oligosaccharides, soyabean oligosaccharides, polyols and polydextrose (158-160). 
 
3.4.3   Synbiotics 
The term synbiotic is used when a product contains both probiotics and prebiotics. 
Because the word alludes to synergism, this term should be reserved for products in 
which the prebiotic compound selectively favors the probiotic compound (153). 
This combination could improve the survival of the probiotic organism, because its 
specific substrate is readily available for its fermentation, and result in 
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Colonic metabolism of lactose, in addition to lactase activity and transit in the 
small intestine, might be involved in the pathophysiology of lactose intolerance. 
However, few studies have been conducted to investigate this topic. This 
dissertation is mainly devoted to describing the possible role of composition and 
metabolic activities of the colonic microbiota in lactose intolerance and the 
possibility to modulate the colonic microbiota with targeted use of dietary 
supplementations. Results of these studies may not only aid to design strategies for 
dietary management of lactose intolerance, but will also lend more understanding 
to colonic metabolism of other undigestible carbohydrates, such as prebiotics, and 
the health relevance of this process. For studying colonic metabolism of lactose, 
proteomic techniques can be promising tools for interpreting the metabolic 
pathways. Furthermore, studies on the small intestinal transit and digestion of 
lactose would help to clarify possible involvement of the colon in lactose 
intolerance. 
 
The aims of this dissertation were: 
(i)  to study transit and digestion of lactose in the small intestine for clarifying 
possible involvement of the colon in lactose intolerance; 
(ii) to investigate whether the composition and metabolic activities of the 
colonic  microbiota play a role in lactose intolerance; 
(iii) to investigate effects of dietary supplementation of pre- and probiotics on 
the colonic microbiota and lactose-induced symptoms; 
(iv) to explore proteomic techniques for studying metabolism of lactose by the 
colonic microbiota and for monitoring the alteration in metabolic activities 
of the colonic microbiota during dietary supplementation. 
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1. Transit and digestion of lactose in the small intestine in lactose 
digesters and maldigesters 
 
To investigate the effect of lactose on OCTT and the possible mechanisms 
underlying the effects, degree of lactose digestion in the small intestine (indicated 
with lactose digestion index, LDI) and OCTT of lactose and glucose were 
compared between lactose digesters (n=13) and maldigesters (n=20). The two 
parameters were also compared between well-classified lactose tolerant (n=7) and 
intolerant maldigesters (n=5) to investigate whether the difference in onset of 
symptoms could result from differences in digestion and transit of lactose in the 
small intestine (Appendix 1). 
 
2. Do composition and metabolic activities of the colon microbiota play 
a role in lactose intolerance? 
 
2.1  Bacteria with ß-galactosidase activity in feces from lactase non-persistent 
subjects 
ß-galactosidase is the bacterial enzyme that catalyzes the first step of lactose 
fermentation in the colon and is often measured as an indication of the capacity of 
the colonic microbiota to ferment lactose. The percentage and composition of 
bacteria in feces with ß-galactosidase activity were determined in 28 lactase non-
persistent subjects and compared between lactose tolerant (n=7) and intolerant 
subjects (n=5). The method used to determine those bacteria combines a colony-lift 
filter assay with X-gal (5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside) as 
substrate for differentiation and the fluorescent in situ hybridization technique for 
identification (Appendix 2). 
 
2.2  Comparison of the colonic capacity to ferment lactose in vitro between 
lactose tolerant and intolerant subjects 
Feces from well-classified lactose tolerant (n=7) and intolerant subjects (n=5) was 










collected for measurement of lactose, glucose, galactose, SCFA and D- and L- 
lactate. Fecal bacterial composition was determined by FISH (Appendix 3). 
 
3.  Effects of yogurt and bifidobacteria supplementation on the colonic 
microbiota and lactose-induced symptoms in lactose intolerant 
subjects 
 
After lactose intolerant subjects (n=11) had ingested yogurt and bifidobacteria for 2 
w, ß-galactosidase activity in their feces was measured and fecal bacterial 
composition was determined by FISH. PCR and DGGE were used to study 
dynamics of the bifidobacterial population in feces. Furthermore, the effects of the 
supplementation on the endogenous lactase activity in the small intestine and 
lactose-induced symptoms were studied as well (Appendix 4). 
 
4. Exploring proteomic techniques for studying lactose metabolism by 
the colonic microbiota 
 
Bifidobacterium was chosen as a model bacterium for studying fermentation of 
lactose by the colonic microbiota. Differences in cytoplasmic protein expression of 
Bifidobacterium animalis, breve and longum grown on different carbohydrates 
(lactose, glucose, glactose) were analyzed with the SELDI-TOF MS Proteinchip 
technology and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). After fractionation by SDS-PAGE, differentially-expressed proteins 














1.  Fermentation of lactose by the colonic microbiota may play a role in 
lactose intolerance 
 
The lactose tolerant and intolerant subjects did not differ in LDI or OCTT of 
lactose, which suggests the involvement of other pathologic mechanisms in lactose 
intolerance. We hypothesize that colonic metabolism of lactose is one of these 
mechanisms (Appendix 1).  During the in vitro incubation of feces with lactose, 
the lactose intolerant group produced D- and L-lactate, acetate, propionate and 
butyrate significantly faster than the tolerant group. In the intolerant group, the 
amount of acetate, propionate, butyrate and L- lactate produced was higher than 
that in the tolerant group. The results indicate that a faster and higher production of 
microbial intermediate and end metabolites during colonic fermentation of lactose, 
may be related to the development of lactose-induced symptoms (Appendix 3). 
However, the degree and rate of lactose hydrolysis in the colon does not play a role. 
During colonic fermentation, lactose is first hydrolyzed to glucose and galactose, 
which is catalyzed by ß-galactosidase. We found that bacterial ß-galactosidase 
activity is abundant in the colon as 80.6% (mean, SD: 12.1, range: 47.8%-100%) of 
the cultured fecal bacteria possess this activity. The lactose tolerant and intolerant 
subjects did not differ in the percentage or composition of the bacteria with ß-
galactosidase activity or ß-galactosidase activity in feces (Appendix 2). We 
assume that lactose itself will not present a large osmotic burden to the colon as it 
should be quickly degraded by the colonic microbiota. This assumption is 
supported by observations that the tolerant and intolerant groups did not differ in 
the rate or degree of hydrolysis of lactose or production of glucose and galactose 
(Appendix 3). We propose that after lactose is hydrolyzed, the subsequent 
fermentation of glucose and galactose may play a role in the pathophysiology of 
lactose intolerance. 
      Whether colonic fermentation of lactose would influence lactose intolerance, 
either aggravates or alleviates it, depends on the balance between the ability of the 
colonic microbiota to ferment lactose and the ability of the colon to remove the 
fermentation metabolites. We assume that the absorption rate of the colon is not 
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fermentation of lactose. This leads to temporary accumulation of SCFA and other 
metabolites in the colon, which plays a role in the onset of lactose-induced 
symptoms possibly through their osmotic load, altering intestinal motility or 
causing colonic hypersensitivity. 
      The in vitro results suggest that colonic fermentation of lactose may play a role 
in lactose intolerance. This provides the basis for the following studies: (i) to 
investigate whether the colonic microbiota could be modulated by dietary 
supplementation for the purpose of alleviating symptoms; (ii) to explore 
proteomics techniques to study metabolic pathways of lactose fermentation by the 
colonic microbiota; (iii) to design an in vivo study to verify the observations of the 
in vitro study. 
 
2. Yogurt and bifidobacteria supplementation modifies the colonic 
microbiota and alleviates lactose-induced symptoms in lactose 
intolerant subjects 
 
Our results suggest that colonic fermentation of lactose may play a role in lactose 
intolerance (Appendix 3). This raises the question whether we can modulate the 
composition and metabolic activities of the colonic microbiota in such a way that 
lactose intolerance could be attenuated. In this study (Appendix 4), 2-w 
supplementation of probiotic bacteria Bifidobacterium longum and a yogurt 
enriched with Bifidobacterium animalis increased the numbers of total cells, total 
bacteria and Eubacterium rectale/Clostridium coccoides group and ß-galactosidase 
activity in feces of lactose intolerant subjects. The supplementation did not increase 
the endogenous lactase activity in the small intestine. Symptoms of lactose 
intolerance decreased after the supplementation. The increase in bacterial numbers 
could be attributed to the lactose contained in the yogurt which can be considered 
as a prebiotic for people with lactose maldigestion (162,163). Reduction in 
symptoms could be caused by adaptation to lactose consumption (80) and changes 
in the composition and metabolism of the colonic microbiota. In conclusion, 
supplementation of yogurt and a probiotic strain modified the amount and probably 
the metabolic activities of the colonic microbiota of lactose intolerance subjects. 
  
40 
The changes in the colonic microbiota may play a role in alleviation of intolerant 
symptoms. 
 
3.  Exploring proteomic techniques for studying lactose metabolism by 
the colonic microbiota 
 
In the above studies (Appendix 2-4), the composition of the colonic microbiota 
was determined by FISH, DGGE and an X-gal assay, and the metabolic activities 
of the colonic microbiota were investigated by in vitro incubation and by 
determination of enzyme activities. Development of new techniques will facilitate 
the studies on the role of the colonic microbiota in health and disease. Proteomic 
techniques might aid to interpret the metabolic pathways of lactose metabolism by 
the colonic microbiota. In this study (Appendix 5), the SELDI-TOF MS 
Proteinchip technology and sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) could discern differences in protein expression of 
bifidobacteria grown on lactose, glucose and galactose. With LC-MS/MS, proteins 
related to Bifidobacterium were identified, which included enzymes for metabolism 
of lactose, glucose and galactose. The applied approaches are promising in 
studying metabolism of lactose and other substrates in a complex bacterial 
ecosystem such as the colonic microbiota, but need further development. For 
instance, when fractionation by SDS-PAGE and identification by LC-MS/MS is 
combined with stable isotope labeling, it will facilitate identification of proteins of 
which expression is induced by specific substrates.  
 
4.  Lactose accelerates the oro-cecal transit in lactose maldigesters  
 
Studies on digestion and transit of lactose in the small intestine would help to 
clarify possible involvement of the colon in lactose intolerance. In the study 
(Appendix 1), we observed that ompared to glucose, lactose triggers a faster transit 
in the small intestine in lactose maldigesters, but not in digesters. The accelerated 
transit is not the result of intestinal distention caused by osmotic load from 
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amount of fluid the maldigested lactose would attract to the intestine in lactose 
digesters and maldigesters. The amounts are unlikely to cause intestinal distention 
and the difference in the amount between digesters and maldigesters is unlikely to 
cause the difference in OCTT. We hypothesize that presence of maldigested lactose 
in the intestinal lumen plays a role in the alteration of intestinal transit by affecting 
the intrinsic factors that regulate intestinal motility. Postprandial motility of the 
gastrointestinal tract is controlled by nerves, hormones and paracrine mediators 
(164). It might be possible that undigested lactose alters the motility of the intestine 
by stimulating the secretion of certain gastrointestinal hormones, or by stimulating 
the neural activities of certain chemosensitive receptors or osmoreceptors. 
We speculate that this hypothesis can be extended to explain the accelerated 
intestinal transit in malabsorption of other sugars and some food components, for 
instance, fructose and sorbitol (165-170). Malabsorption of lactose, fructose and 
sorbitol can be related, as fructose and sorbitol malabsorption are common when 
lactose malabsorption is present (168). 
      The lactose tolerant and intolerant subjects did not differ in degree of lactose 
digestion (LDI) or OCTT of lactose. This suggests the involvement of other 







Comparison of colonic metabolism of lactose in vivo between lactose tolerant 
and intolerant subjects using stable isotopes 
 
Our in vitro study indicates that a faster and higher production of microbial 
intermediate and end metabolites during colonic fermentation of lactose, may play 
a role in lactose-induced symptoms (Appendix 3). However, the in vitro system 
may not be a perfect reflection of the in vivo situation. The culturing conditions are 
different from those in the colon. Colonic factors, e.g. removal of the metabolites, 
gut secretions and immunology and interaction with mucosal cells, are not studied. 
Therefore, our in vitro observations need to be verified by in vivo studies. 
      In vivo studies on colonic metabolism of certain substrates with humans are 
scant as they are hampered by difficulties in sampling in situ and quantitative 
delivery of substrates to the colon. To circumvent these difficulties, several 
approaches using stable isotopes can be considered. 
 
1. Oral administration of 13C-lactose-ureide 
 
Background: The human gut tissue possesses no allantoicase-like activity to split 
the bond between glycosyl and ureide (171). Therefore, glycosyl ureides cannot be 
absorbed in the small intestine. In the colon, glycosyl ureides can be degraded by 
Clostridium innocuum strains which belong to the normal intestinal microbiota of 
infants and adults (172). After the glycosyl-ureide bond is split, the glycosyl and 
ureide will be further metabolized by colonic bacteria. Glycosyl ureides are used as 
a marker for measurement of the OCTT (173). 
Approaches: Tracer amount of 13C-lactose-ureide and 25 g of lactose dissolved in 
water will be administered orally in lactose maldigesters. Peripheral blood samples 
will be collected for measurement of 13C-acetate. Breath samples will be collected 
for determination of OCTT. 13C-lactose-ureide is not absorbed in the small 
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will be fermented by the colonic bacteria together with the maldigested unlabeled 
lactose. The kinetics of 13C-acetate in the peripheral blood will reflect the kinetics 
of colonic fermentation of maldigested lactose. 
Disadvantages: The hydrolysis of the lactose-ureide bond by bacterial enzymes is 
the rate-limiting step in bacterial degradation of lactose-ureide (174). However, 
there is no detailed information available on how long this step takes or whether 
the time varies among individuals. If there is a large inter-individual variation, the 
fermentation of 13C-lactose-ureide cannot represent the fermentation of lactose. 
 
2.  Isotope-dilution technique 
 
Background: The principle of the isotope-dilution technique is as following: in a 
closed volume at steady-state (production and elimination rates are at equilibrium), 
the labeled tracer is infused at a constant and known rate until a new steady-state is 
reached. Blood samples are collected at regular intervals. From the isotopic 
enrichment in blood at steady-state the production or elimination rates of the 
metabolite of interest can be calculated (139). The isotope-dilution technique has 
been used to quantitatively estimate colonic fermentation of non-digestible 
carbohydrates (137-139,175). 
Approaches: Lactose maldigesters will receive a primed, constant and intravenous 
infusion of [l-13C]acetate for 7 h. 25 g of lactose will be ingested 1 h after the tracer 
infusion starts. Arterialized venous blood samples will be collected for 
determination of the total production and the production rate of [l-13C] acetate. 
Disadvantages: As absorption of lactose in the small intestine varies among lactose 
maldigesters, the amount of lactose entering the colon varies. The amount of 
lactose in the colon may influence the rate of bacterial fermentation. Therefore, the 
possible differences in total production and the production rate of [l-13C] acetate 











3. Colon-delivery capsules 
 
Various colon-specific drug delivery systems have been developed (176). The 
release triggering mechanisms of these capsules can be pH- or time-dependent, 
microbiota-activated, pressure-dependent, etc. However, the delivery capacity of 
these systems may not be sufficient to deliver the amount of lactose averagely 
maldigested after ingestion of 25 g of lactose in maldigester (~20 g). 
 
 
4.  Colon-infusion catheters 
 
Different types of catheters have been implanted into the colon for various 
purposes (104,177). Although the procedure can be experience-dependent and 
somewhat invasive, colon-infusion catheters allow quantitative delivery of large 
amounts of substrates. Therefore, for our purpose of studying colonic fermentation 
of lactose in vivo, colon-infusion catheters can be an appropriate approach. An in 
vivo study on colonic fermentation of lactose using stable isotopes delivered via a 






The results presented in this dissertation suggest that colonic metabolism of lactose, 
in addition to the small-intestinal lactase activity and transit, may play a role in the 
pathophysiology of lactose intolerance. During fermentation of lactose by the 
colonic mictobiota, the rate and magnitude of production of metabolites could be 
among the factors contributing to the onset of lactose-induced symptoms. This 
observation implies that in studies on colonic fermentation of carbohydrates, i.e. 
prebiotics, the rate and magnitude of fermentation can be of health relevance. 
      Dietary supplementation of pre-, pro- or synbiotics provides a promising 
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Background: The transit time of the small intestine, in addition to the lactase 
activity, may also influence lactose digestion and thus play a role in the occurrence 
of lactose intolerance. The objective of this study was to investigate the effect of 
lactose on the oro-cecal transit time (OCTT) in lactose digesters and maldigesters 
and the possible mechanisms underlying the effects.  
Subjects and methods: Twenty-eight Chinese subjects and 16 Dutch subjects 
underwent one glucose and one lactose challenge in two single-blinded tests. 
Twenty of the Chinese subjects without complaints after glucose underwent 
another lactose challenge. A 6-h symptom score (SSC) was recorded, breath 
hydrogen concentration measured and OCTT after consumption of glucose and 
lactose determined with the lactose-[13C] ureide breath test. The lactose digestion 
index (LDI) was determined in the Dutch and the 20 Chinese subjects with the 
13C/2H-glucose test. 
Results: Lactose digesters (n=13) and maldigesters (n=20) were classified based 
on the results of LDI and breath hydrogen test. The OCTT after challenges of 
lactose and glucose did not differ in digesters, while in maldigesters OCTT after 
the lactose challenge was shorter than that after glucose. There was no difference in 
OCTT after the glucose challenge between maldigesters and digesters. However, 
OCTT after the lactose challenge in maldigesters was shorter than that in digesters. 
LDI of the digesters was significantly higher than that of the maldigesters. OCTT 
after the lactose challenge is not correlated to LDI in maldigesters or in digesters. 
Based on SSC after the one glucose and two lactose challenges, a tolerant (n= 7) 
and an intolerant (n= 5) group were classified in the Chinese subjects. The two 
groups did not differ in LDI or OCTT after the lactose challenge. OCTT after the 
lactose challenge was not correlated to SSC or LDI.  
Conclusions: Lactose triggers faster oro-cecal transit in lactose maldigesters, but 
not in digesters. This, however, cannot be explained by intestinal distension 
resulting from the osmotic load posed by maldigested lactose and suggests a direct 











Several factors are considered to be involved in the occurrence of lactose 
intolerance, including the amount of lactose ingested, small-intestinal lactase 
activity, small-intestinal transit, and colonic processing of lactose (1,2). In lactose 
maldigesters, ingestion of a certain amount of lactose may result in acceleration of 
small intestinal transit, which is suggested to be caused by the osmotic load of 
maldigested lactose (3,4). However, scant attention has been paid to insights into 
the effect of the osmotic load of maldigested lactose on small intestinal transit. The 
accelerated transit could also be caused by intrinsic factors, e.g. lactose 
maldigesters, per se, might have a faster transit than digesters. In the present study, 
the degree of lactose digestion in the small intestine (as indicated with the lactose 
digestion index, LDI) and the oro-cecal transit time (OCTT) after challenges of 
glucose and lactose were compared between lactose digesters and maldigesters and 
between lactose tolerant and intolerant subjects. By measuring the degree of lactose 
digestion, the osmotic load posed by maldigested lactose can be estimated and thus, 
the correlation between osmotic load and OCTT can be analysed. Glucose is 
readily absorbed in the small intestine. Comparison of OCTT after the glucose 
challenge between lactose digesters and maldigesters can help to clarify whether 
lactose maldigesters, when without the influence of osmotic load, still have a faster 
transit than digesters. The lactose digesters and maldigesters were classified from a 
population with genetically determined lactase persistence (Dutch) and that with 
genetically determined lactase non-persistence (Chinese), respectively.  
    The objective of this study was to investigate the effect of lactose on OCTT in 
lactose digesters and maldigesters and the possible mechanisms underlying the 
effects. The results of this study may help to understand the pathophysiology of 














Twenty-eight healthy Chinese subjects (temporarily living in The Netherlands, 16 
females and 12 males, age range 20-31 years) and 16 healthy Dutch subjects (12 
females and 4 males, age range 18-60 years) were recruited for this study. None of 
the subjects had diabetes or gastrointestinal disorders, or had taken antibiotics or 
laxatives during the three months prior to the study. Every subject signed a 
declaration of informed consent. The study was approved by the Medical Ethical 
Committee of the Groningen University Hospital and Faculty of Medical Sciences. 
 
One glucose and two lactose challenges for the Chinese subjects 
 
In order to well classify lactose tolerant and intolerant subjects from the Chinese 
subjects, the 28 Chinese subjects underwent two lactose challenges and one 
glucose (placebo) challenge.  They first underwent a challenge of 25 g glucose and 
a challenge of 25 g lactose (lactose challenge 1) in two single-blinded tests (test 1 
and 2). During both challenges a 6-h symptom score (SSC) was recorded and 
breath samples were collected for measurement of breath hydrogen concentration 
and OCTT after the challenge of glucose or lactose. The glucose challenge served 
as a placebo control. Twenty of the 28 subjects who reported SSC  2 after glucose 
challenge underwent a second lactose challenge of 25 g 13C-enriched lactose 
(lactose challenge 2), during which SSC was recorded, breath samples and blood 
samples were collected for determination of OCTT and lactose digestion index 
(LDI), respectively. 
 
One glucose and one lactose challenge for the Dutch subjects 
 
The 16 Dutch subjects underwent a challenge of 25 g glucose and a challenge of 25 
g 13C-enriched lactose in two single-blinded tests. Breath samples were collected 
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lactose and breath hydrogen concentration, and blood samples were collected 





SSC was recorded as described before (2). Briefly, during 6 h after the lactose 
consumption, the subjects scored hourly the occurrence and severity of flatulence 
and abdominal cramps using a ranked scale: 0 = none, 1 = mild, 2 = moderate and 
3 = severe. The occurrence and consistency of bowel movements were also 
registered: 0 = normal, 1 = loose, 2 = watery. To weigh the different complaints 
according to their significance, the scores were multiplied by different factors: 1 = 
flatulence, 2 = abdominal cramps, 4 = stool consistency. SSC is the sum of all 
scores recorded in 6 h. For Chinese subjects, the SSC after the glucose and the two 
lactose challenges was combined together to define subjects who were ‘truly’ 
lactose tolerant or intolerant according to the following criteria: (1) SSC  2 after 
glucose challenge; (2) SSC of the two lactose challenges was consistent. Subjects 
with SSC  2 in both lactose challenges were classified as lactose tolerant, and 
those with SSC > 2 as lactose intolerant. 
 
Measurement of OCTT and LDI, determination of breath hydrogen 
OCTT was measured with the lactose-[13C] ureide breath test as described 
previously (5). OCTT was defined as the time elapsed between ingestion of the test 
substrate and a sustained (> 3 time points) rise in the 13C abundance in breath CO2  
of > 2·0 13C above baseline. In the case of a substrate which is digested and 
absorbed in the small intestine, OCTT is actually the oral-cecal transit time of 
lactose-[13C] ureide under the influence of the substrate. Breath hydrogen 
concentration was analyzed as described before (6). LDI was determined with the 
13C/2H-glucose test as described earlier (7) with a slight modification in calculation: 
LDI was not calculated as the mean value of the 13C/2H concentration ratio in 









i.e. the time-point of the peak 2H-glucose concentration, the point before and after 
this point. The time point of the peak 2H-glucose concentration, which is strongly 
influenced by the gastric emptying rate, has been shown to vary among individuals. 
With this new method of calculation, the individual differences in gastric emptying 
rate can be better compensated. The data from the authours’ previous study (7) 
were re-calculated with this method to establish a new cut-off value for classifying 
lactose digesters and maldigesters. 
Data analysis 
 
Data are expressed as mean ± standard deviation (SD). The Student t-test (unpaired, 
two-tailed) and the Mann-Whitney U test (independent samples, two-tailed) were 
applied as appropriate to assess differences in LDI and in OCTT between the 
maldigesters and digesters and between the lactose tolerant and intolerant subjects. 
The Student t-test (paired, two-tailed) and the Wilcoxon signed ranks test were 
used as appropriate to assess differences in OCTT between lactose and glucose in 
digesters and maldigesters, and between lactose challenge 1 and 2 in the Chinese 
subjects, and to assess differences in SSC between glucose and lactose challenges. 
Correlation was assessed by calculating the Spearman correlation coefficients as 
appropriate. P < 0.05 was regarded as significant. All analyses were performed 
using SPSS 12.0 for Windows software (SPSS Inc., Chicago, IL, USA). Figures 






Classification of lactose digesters and maldigesters with LDI and breath -
hydrogen 
 
After the data from our previous study (7) were re-calculated for LDI, a new cut-
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2SD). Subjects with LDI lower than or equal to 0.29 and with a positive breath 
hydrogen response after ingestion of 25 g of lactose were classified as lactose 
maldigesters, otherwise the subjects were classified as digesters. When LDI and 
breath hydrogen response were not in agreement, the subject would not be included 
in the data analysis. Twenty subjects (19 Chinese, one Dutch) were classified as 
lactose maldigesters, and 13 (Dutch) as digesters. 
LDI of the digesters (0.59 ± 0.12, mean ± SD) was significantly higher than that 
of the maldigesters (0.17 ± 0.06, mean ± SD) (P < 0.001). 
After the glucose challenge, all subjects (Chinese and Dutch) had a negative 
breath hydrogen response. After the lactose challenge, a positive breath hydrogen 




An increase in breath-13CO2 was measured in 15 and 6 of the maldigesters and 
digesters, respectively, after intake of glucose, and in 17 and 7 of the maldigesters 
and digesters, respectively, after lactose (lactose challenge 1 for Chinese). An 
increase in breath-13CO2 was measured in 17 of the 20 Chinese maldigesters who 
underwent the second lactose challenge. 
In the case of digesters, there was no difference in OCTT  between lactose and 
glucose (P = 0.249)  (Fig. 1). In maldigesters, OCTT after the lactose challenge 
(OCTT of challenge1 for Chinese) was significantly shorter than that of glucose (P 
< 0.001). The digesters and maldigesters did not differ in OCTT after the glucose 
challenge (P = 0.970), but OCTT after the lactose challenge of the maldigesters 
was significantly shorter than that of the digesters (P < 0.001). 
OCTT after the lactose challenge (17 Chinese and one Dutch, lactose challenge 
2 for Chinese) is not correlated to LDI in maldigesters (r = -0.090, P = 0.723) (Fig. 
2) or in digesters (r = -0.595, P = 0.159) (not shown). 
There was no difference in OCTT between lactose challenge 1 and 2 of the 20 











Table 1. Comparison of the lactose digestion index (LDI) and oro-cecal transit time (OCTT) 
after the lactose challenge between lactose tolerant and intolerant subjects (mean ± SD) 
 
  n LDI OCTT * 
Tolerant 7 0.22 ± 0.08 144 ± 58 
Intolerant 5 0.16 ± 0.05 113 ± 68 
 






















Figure 1. The oro-cecal transit time (OCTT) after challenges of lactose and glucose in 
lactose maldigesters and digesters. md-lac1: lactose challenge 1, maldigesters, n = 17;  
md-lac2: lactose challenge 2, maldigesters, n = 17; md-glu: glucose, maldigesters, n = 15; 
d-lac: lactose, digesters, n = 7; d-glu: glucose, digesters, n = 6; *: P < 0.001 compared with 





























After the glucose challenge, 8 and 1 of the 28 Chinese and the 16 Dutch subjects, 
respectively, had SSC > 2 while all of them had a negative breath hydrogen 
response. Only one Dutch subject, a lactose digester, reported SSC > 2 after the 
lactose challenge. For the Chinese subjects, SSC of glucose (1.8 ± 2.8, mean ± SD) 
was lower than SSC of lactose (challenge 1 (5.4 ± 6.1, mean ± SD), (P < 0.001); 
challenge 2 (3.0 ± 3.2, mean ± SD), P =0.018). In lactose challenge 2 with 20 
Chinese subjects, SSC was not correlated with either LDI (r = -0.184, P = 0.436) or 
OCTT (r = -0.112, P = 0.659). 
 
Tolerant versus intolerant 
 
Based on the SSC of the one glucose and two lactose challenges, a lactose 
intolerant (n=5) and a tolerant group (n=7) were classified in the Chinese subjects 
according to the criteria described above. The two groups did not differ in LDI (P = 
0.073), although there was a trend towards a lower LDI for the intolerant subjects. 
OCTT after the lactose challenge of the intolerant group was shorter than that of 
the tolerant group, but the difference was not significant (P = 0.440) (Table 1). 
OCTT after the glucose challenge could be measured only in two intolerant (285 
and 300 min, respectively) and three tolerant subjects (165, 315 and 345 min, 
respectively) and therefore, was not included in statistic analysis. For the 12 
subjects, SSC was not correlated with LDI of lactose (r = -0.377, P = 0.226) or 





In the present study, OCTT after challenges of lactose and glucose was 
investigated in lactose digesters and maldigesters. Lactose shortened OCTT in 
maldigesters but not in digesters, while OCTT after the glucose challenge was not 

























Figure 2. Correlation between the oro-cecal transit time (OCTT) after the lactose challenge 




The mechanisms behind the lactose-induced acceleration of the small bowel 
transit in lactose maldigesters are not clear. The osmotic load posed by maldigested 
lactose is suggested to be the cause of the accelerated transit. The osmotic load 
causes secretion of fluid which causes dilatation of the intestine. Dilatation of the 
intestine induces an acceleration of small intestinal transit (1). The same 
mechanism is also suggested for accelerated transit after intake of lactulose, a sugar 
that  is composed of galactose and fructose and cannot be digested in the small 
intestine (8,9). It has been shown that a hyperosmolar solution increases duodenal 
motor activity in a dose-dependent fashion. This effect speeds up the transit of 
intestinal contents and may serve to provide a means whereby hyperosmolar 
material is removed from the duodenum (10). This increase in motility may be due 
to two mechanisms, i.e. the distension resulting from osmotic equilibration or the 
triggering of a local osmoreceptor control of duodenal motility (11). When we 
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estimate the amount of fluid maldigested lactose would attract to the intestine in 
the lactose digesters and maldigesters, it is unlikely that this amount could cause 
intestinal distension which would result in alteration in the intestinal transit. We 
measured the degree of lactose digestion (indicated with LDI). On average, the 
lactose digesters and maldigesters digested 59% and 17% of the 25 g lactose 
ingested, respectively. The maldigested lactose, i.e. 10.2 g and 20.8 g, respectively, 
represents osmotic loads of 35 and 70 mOsm, which would bring approximately 
120 and 240 ml water to the small intestine, respectively (12). It is unlikely that a 
volume of 120 or 240 ml would cause distension and that a difference of 120 ml 
could cause the difference in OCTT, considering that the volume of the small 
intestine is about 6 litres and approximately 9 litres fluid is absorbed every day (13).  
As alteration in the transit is probably not caused by distension resulting from 
osmotic equilibration, it is hypothesized that maldigested lactose alters the transit 
by affecting the intrinsic factors that regulate intestinal motility. A hyperosmolar 
solution can increase intestinal motility by triggering local osmoreceptor control 
(11). Osmoreceptors are reported to exist in the upper duodenum and can increase 
duodenal motility and slow down gastric emptying as a result of a local 
osmoreceptor control mechanism. The effect of osmoreceptors is dose-dependent 
and regardless of whether intestinal distension is preserved or removed (10,11,14). 
We did not observe a dose-dependent correlation between the magnitude of 
osmolarity and change in intestinal transit as OCTT is not correlated to the amount 
of maldigested lactose. This suggests the involvement of other mechanisms 
underlying the accelerated transit, even if osmoreceptors would contribute partly to 
the effect. Postprandial motility of the gastrointestinal tract is controlled by nerves, 
hormones and paracrine mediators. Food intake is succeeded by the release of 
many gastrointestinal regulatory peptides such as pancreatic polypeptide, peptide 
YY  and neuropeptide Y (15). Chemosensitive receptors are found to be present in 
the intestine and intervene in gastrointestinal motor coordination, e.g. 
glucoreceptors in the duodenum and jejunum (16, 17). It might be possible that 
undigested lactose alters the intestinal motility by stimulating the secretion of 
certain gastrointestinal hormones, or by stimulating the neural activities of certain 









maldigesters mainly of Chinese subjects, another explanation could be that Chinese 
and Dutch subjects differ in some intrinsic factors that are involved in the 
regulation of gastrointestinal motility, which may lead to a different response in 
gastrointestinal motility towards the same substrate. Yue et al. (18) observed an 
ethnic difference in OCTT between Chinese and Caucasian subjects in the response 
to codeine. The possible explanations given are the differences in dietary habit (19) 
and endogenous opioids (20,21) involved in the regulation of gastrointestinal 
motility. In the present study, we did not observe differences in OCTT after the 
glucose challenge between the tolerant and intolerant group. However, this cannot 
exclude the possibility of different response from the Chinese and Dutch towards 
other sugars, especially those that are maldigested. 
It is speculated that this hypothesis can be extended to explain the accelerated 
intestinal transit in malabsorption of other sugars and some food components, for 
instance, fructose and sorbitol (22-27). Malabsorption of lactose, fructose and 
sorbitol can be related, as fructose and sorbitol malabsorption are common when 
lactose malabsorption is present (27).  
These results indicate that OCTT is not a major factor in the occurrence of 
symptoms of lactose intolerance, as SSC was not correlated with OCTT and there 
was no significant difference in OCTT between lactose tolerant and intolerant 
subjects. Similar results were observed by Roggero et al (28). In other studies it 
was shown that a slow oro-cecal transit contributes to less symptoms in lactose 
maldigesters (2,3,29,30). When the degree of lactose digestion and transit time in 
the small intestine are the same, what could be the reason that some maldigesters 
develop symptoms while others do not? One possibility could be the difference in 
the colonic fermentation of maldigested lactose (31). Another possible cause could 
be the difference in symptom perception (32)  and/or intestinal dismotility, as 
suggested for irritable bowel syndrome (IBS) (33-35). IBS is shown to be strongly 
related to subjective lactose intolerance (36).  
In conclusion, we observed that lactose accelerates the oro-cecal transit in 
lactose maldigesters, which is not caused by intestinal distension resulting from the 
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undigested lactose itself in the intestinal lumen plays a role in acceleration of 
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Background: Previous studies suggested that besides the maldigestion of lactose 
in the small intestine, the colonic processing of lactose might play a role in lactose 
intolerance. ß-galactosidase is the bacterial enzyme which catalyzes the first step of 
lactose fermentation in the colon. 
Subjects and methods: We propose a practical method to differentiate and 
identify bacteria with ß-galactosidase activity in faeces which combines a colony-
lift filter assay with X-gal (5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside) as 
substrate for differentiation and the fluorescent in situ hybridization technique for 
identification. The method was applied to faeces from lactase non-persistent 
subjects.  
Results: After 28 subjects had undergone one glucose and two lactose challenges, 
consistent intolerant (n=5) and tolerant (n=7) groups were defined according to 
their symptom scores. Of the 28 faecal samples, 80.6% (mean, SD: 12.1, range: 
47.8%-100%) of the total cultured bacteria were found to possess ß- galactosidase 
activity. The tolerant and intolerant groups did not differ in the percentage or 
composition of the bacteria with ß-galactosidase activity or ß-galactosidase activity 
in faeces. 
Conclusions: The bacterial ß-galactosidase is abundant in the colon. The 
percentage or composition of the bacteria with ß-galactosidase activity in faeces is 











Several studies have been carried out to clarify the mechanisms involved in 
lactose intolerance (1). We recently demonstrated that lactose intolerant subjects 
with mild symptoms or with diarrhoea did not differ in degree of lactose digestion 
in the small intestine or orocecal transit time (2), which indicates that besides the 
digestion of lactose in the small intestine, other factors might influence the 
development of lactose intolerance, for instance, colonic factors (3,4). Therefore, 
colonic microbiota which ferment lactose, have become a focus of lactose 
intolerance research. In our subsequent study in which faecal bacteria were 
quantified with fluorescent in situ hybridization (FISH), the total number of 
hybridizable bacteria was found to correlate negatively with symptom scores (SSC) 
of lactose intolerance, based on which it was suggested that a higher fermentation 
capacity of the colonic microbiota contributes to the reduction of lactose 
intolerance (5).  
The colonic capacity to ferment lactose could be determined by the amount, 
composition and enzyme activity of the lactose-fermenting bacteria in the colon. ß-
galactosidase is the enzyme that catalyzes the first step of lactose fermentation in 
the colon: the hydrolysis of lactose into glucose and galactose which will 
subsequently be degraded. Among the lactose-fermenting bacteria, the ß-
galactosidase activity may vary up to 4-fold (6). Therefore, the amount and 
composition of the bacteria with ß-galactosidase activity could be determinants of 
the fermentative capacity of lactose in the colon and studies on this topic might 
elucidate the possible role of colonic microbiota in lactose intolerance.  
In the present study, a method to differentiate and identify bacteria with ß-
galactosidase activity (intra- and extra-cellular) was developed and applied to 
faecal samples from subjects with genetically determined low lactase activity to 
investigate whether the relative amount (percentage) and composition of bacteria 
with ß-galactosidase is related to the development of lactose intolerance. For 
differentiation of bacteria with the enzyme activity, faecal bacteria were first 
cultured on a general medium agar instead of a medium containing X-gal and then 










influence of X- ß-galactosidase activity gal on growth of the bacteria. The bacteria 
were identified with FISH. 
 
 




Twenty-eight healthy Chinese subjects (temporarily living in The Netherlands, 
16 female and 12 male, age range 20-31 years) were recruited for this study. All 
subjects did not have diabetes or gastrointestinal disorders, and had not taken 
antibiotics or laxatives during the three months prior to the study. Every subject 
signed a declaration of informed consent. The study was approved by the Medical 
Ethical Committee of the Groningen University Hospital and Faculty of Medical 
Sciences. 
 
Culturing of anaerobic bacteria in faeces 
 
Faeces from each subject was collected in a sterile bag and maintained 
anaerobically with AnaeroGenTM COMPACT (Oxoid Limited, Hampshire, 
England). After arrival in the laboratory, samples were kept under 4 °C. All faecal 
samples were processed within 2 h after defecation. 
Samples were homogenized by mechanical kneading for 2 min. For each sample, 
10 g was suspended in 40 ml of an anaerobic salt solution (pH: 7.5; ingredients per 
litre: MgSO4 ⋅7H2 O, 0.06 g; NaCl, 0.23 g; K2HPO4, 8.45 g; KH2PO4, 1.52 g; 
NaHCO3, 9.50 g; 0.4% CaCl2, 0.47 ml; 0.02% resazurine, 0.93 ml; gelatine, 0.47 g; 
cysteine, 0.12 g) and vortexed for 3 min together with a few glass beads.  The 
suspension was centrifuged at 170 × g for 1 min and the supernatant was taken into 
an anaerobic chamber (Anaerobic workstation, Concept 400, West Yorkshire, UK; 
10%H2, 10%CO2, 80%N2) and further diluted with the anaerobic salt solution to 
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inoculated on Brucella blood agar (BBA, diameter of the plate: 14 cm) and 
incubated for 72 h. 
 
Differentiation of bacteria with ß-galactosidase activity with X-gal 
 
A ß-galactosidase colony-lift filter assay was carried out to differentiate the 
bacteria with ß-galactosidase activity according to the product protocol of the 
MATCHMAKER Two-Hybrid System (CLONTECH, USA). With this method, 
bacteria with intra- or extra-cellular ß-galactosidase will be detected. After 
incubation for 72 h, for each faecal sample, the dilution with 20-150 colonies per 
plate was selected for enumeration of the total amount of colonies. The colonies on 
the plate were transferred to a Whatman filter (Qualitative, Whatman International 
Ltd Maidstone, England), during which both the filter and agar were marked to 
give an indication for orientation. The plate was kept in the anaerobic chamber for 
another 48 h to let the colonies re-grow for identification of bacteria with ß-
galactosidase activity with FISH. The filter with colonies was submerged in liquid 
nitrogen for 10 sec to disrupt the cells. After thawing, the filter was placed on top 
of another filter pre-soaked in Z buffer/X-gal (ingredients per100 ml: X-gal (5-
bromo-4-chloro-3-indolyl-ß-D-galactopyranoside, 0.134 g, Roche Diagnostics 
GmbH, Mannheim, Germany; ß-mercaptoethanol, 0.27 ml; Na2HPO4.7H2O, 1.61 g; 
NaH2PO4.7H2O, 0.55g; KCl, 0.075g; MgSO4.7H2O, 0.0246g) in a Petri-dish. The 
Petri-dish was sealed with Parafilm and kept under 32 °C for 1 h to let the colour 
develop. Then the amount of blue dots on the filter was counted. 
 
Identification of bacteria with ß-galactosidase activity with fluorescent in situ 
hybridization (FISH) 
 
    For each faecal sample, 18 colonies which expressed ß-galactosidase activity 
were chosen for identification of bacteria with FISH. Separate colonies of diverse 
morphology were picked up randomly. The ß-galactosidase-producing colonies 
were identified by aligning the filter to the agar plate using the orientation marks. 










under -20°C until measurement. The identification of bacteria was carried out by 
using 16S rRNA oligonucleotide probes targeting the major bacterial groups in 
faeces. The probes are listed in Table 1 and were described earlier (7) with the 
exception of the Pep197 probe which was newly developed and validated in our 
laboratory (data not shown). With this set of probes, more than 90% of the total 
bacterial cells in the faeces of adults could be detected. The hybridization and 
visualization of fluorescent cells were carried out according to the methods 
described previously (8). 
 
Symptom score (SSC) 
 
After donating faecal samples, the 28 subjects first underwent a challenge of 25 
g glucose and a challenge of 25 g of lactose in a blinded manner. SSC was 
recorded during the 6 h after the challenge according to the method described 
earlier (2). The purpose of the glucose and lactose challenges was to select subjects 
who did not report complaints after glucose ingestion. A SSC less than 2 was 
considered as ‘no complaints’. Among the 28 subjects, 20 reported a SSC of less 
than 2 after glucose and they underwent another challenge of 25 g of lactose after 
which SSC was also recorded. The SSC after the glucose and the two lactose 
challenges was combined together to define subjects who were ‘truly’ lactose 
tolerant or intolerant according to the following criteria: (1) SSC2 after glucose 
challenge; (2) SSC after the 2 lactose challenges was consistent. Therefore, lactose 
tolerant subjects are defined as having SSC2 after glucose and the two lactose 
challenges; while intolerant subjects are defined as having SSC2 after glucose and 
SSC > 2 after the two lactose challenges. The SSC recorded during the second 
lactose challenge were used in the analysis of possible correlation between bacteria 
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Table 1.  The 16S rRNA oligonucleotide probes used to identify bacteria with ß-
galactosidase activity in faeces 
 
Probes * Targeting groups 
Ato291 Atopobium group 
Bac303 Bacteroides/Prevotella 
Bif164 Bifidobacterium 
Chis150/Clit135 Clostridium histolyticum/lituseburense group 
Ecoli1531 Enterobacteriaceae 
Ecyl387 Eubacterium cylindroides group 
Elgc01 Eubacterium low G+C2 
Erec482 Eubacterium rectale/Clostridium coccoides group 
Lab158 Lactobacillus/Enterococcus 
Pep197 Peptostreptococcus 
Phasco741 Phascolarctobacterium group 





, all probes have been described and validated elsewhere (7) except for Pep197  




 Quantification of ß-galactosidase activity in faeces 
     
    Of the 28 subjects, 12 were defined as lactose tolerant or intolerant according to 
the criteria mentioned above. ß-galactosidase activity in faeces from these 12 
subjects was quantified. Faeces was 1: 19 (w/v) diluted with the anaerobic salt 
solution and 0.5 ml of this suspension was sonicated on ice (4 × 1 min with 15 s 
interval, at an amplitude setting of 24) with a Soniprep 150 ( Beun de Ronde BV, 
Abcoude, the Netherlands) followed by centrifugation (16100 × g, 10 min). The ß-
galactosidase activity in the supernatant was measured by determining the 












     
    Data are expressed as mean ± standard deviation (SD). The Mann-Whitney U 
test (independent samples, two-tailed) was applied to assess differences between 
groups in percentages of ß-galactosidase-producing cells (with total bacteria as 
100%), percentages of Bacteroides/Prevotella, Bifidobacterium and the 
Eubacterium rectale/Clostridium coccoides group (with total ß-galactosidase-
producing cells as 100%) and ß-galactosidase activity in faeces. Correlation was 
assessed by calculating the Spearman correlation coefficients. P < 0.05 was 
regarded as significant. All analyses were performed using SPSS 12.0 for Windows 





The percentage and composition of bacteria with ß-galactosidase activity in 
faeces 
 
For the 28 samples, the counts of total bacteria cultivated on the BBA agar were 
0.9 × 1010 (SD: 0.5 × 1010) cells per g of wet faeces. The colonies that produced 
blue colour on the filter with X-gal were regarded as bacteria with ß-galactosidase 
activity, which would include bacteria with either extra- or intra-cellular ß-
galactosidase. The percentages of colonies with ß-galactosidase activity (with the 
total colonies as 100%) and the composition of the blue colonies (with the blue 
colonies as 100%) are presented in Table 2. On average, in 80.6% (SD: 12.1) of the 
colonies from the faecal samples, the enzyme was found to be present. But the 
percentages varied among different faecal samples, with a range of 47.8 %-100%. 
In total, 504 of the blue colonies were chosen randomly for identification with 
FISH, of which 461 were identified with the 14 group-specific probes. 
Bacteroides/Prevotella was the major ß-galactosidase producer in most of the 
samples, comprising 70% (SD: 21.9) of the chosen blue colonies. Furthermore, of 
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group which was detected in every faecal sample. 9.7% (SD: 13.2) and 7.4% (SD: 
8.3) of the chosen blue colonies, respectively, were identified as Bifidobacterium 
and the Eubacterium rectale/Clostridium coccoides group, and they were found in 
42.9% and 57.1% of the faecal samples, respectively. In some faecal samples, other 
bacterial groups, such as the Atopobium group, Streptococcus/Lactococcus and 
Lactobacillus/Enterococcus, were also found to possess this enzyme activity. No 
colonies responded positively to the probes for Enterobacteriaceae, Eubacterium 
cylindroides group, Phascolarctobacterium group or Veillonella, therefore these 
probes are not included in Table 2. 
 
Association between  the percentages and composition of bacteria with ß-
galactosidase activity in faeces and lactose intolerance 
 
After one glucose and two lactose challenges, 12 subjects were defined as 
lactose intolerant (n=5) or tolerant (n=7) according to the criteria described above.  
The other 16 subjects could not be classified into either of the two groups 
according to our criteria. The SSC, percentages and composition of bacteria with ß-
galactosidase activity, and ß-galactosidase activity in faeces of these two groups 
are summarized in Table 3. 
The two groups were not significantly different in the percentages or composition 
of bacteria with ß-galactosidase activity. There was no significant correlation 
between SSC and percentages of ß-galactosidase-producing colonies (with the total 
colonies as 100%), or the percentages of Bacteroides/Prevotella, Bifidobacterium 
and Eubacterium rectale/Clostridium coccoides group (with the blue colonies as 




Table 2. The percentages of ß-galactosidase-producing colonies (blue/total, with the total colonies as 100%) and the 
percentages of the blue colonies responding positively to different probes (with the blue colonies as 100%) in faeces from 28 



























ed 1 73.9 88.9 5.6 - 5.6 - - - - - - 0.0 
2  80.5 94.4 - - - - - - - - - 5.6 
3  88.2 38.9 38.9 - - - - - 5.6 - - 16.6 
4 78.6 55.6 - 5.6 - - - 5.6 5.6 11.1 5.6 10.9 
5 60.1 22.2 - 22.2 5.6 - - 11.1 - - - 38.9 
6 85.3 66.7 33.3 - - - - - - - - 0.0 
7 86.4 72.2 27.8 - - - - - - - - 0.0 
8 66.7 61.1 11.1 16.7 - 5.6 - - 5.6 - - 0.0 
9 76.9 44.4 22.2 - 5.6 - - - - - - 27.8 
10 78.9 94.4 - - - - - - - - - 5.6 
11 88.5 100.0 - - - - - - - - - 0.0 
12 79.6 94.4 - 5.6 - - - - - - - 0.0 
13 93.9 100.0 - - - - - - - - - 0.0 
14 88.4 94.4 - 5.6 - - - - - - - 0.0 
15 76.2 61.1 - 8.3 - - - - - - - 30.6 
16 96.3 88.9 - 5.6 - - - - - - 5.6 0.0 
17 87.8 77.8 - 22.2 - - - - - - - 0.0 
18 69.4 55.6 27.8 16.7 - - - - - - - 0.0 
19 70.6 88.9 - 11.1 - - - - - - - 0.0 
20 100.0 77.8 - 11.1 - - - - - - 11.1 0.0 
21 90.9 72.2 5.6 16.7 - - - - - - - 5.6 
22 80.3 50.0 27.8 22.2 - - - - - - - 0.0 
23  94.2 72.2 - - - - 27.8 - - - - 0.0 
24 93.2 55.6 22.2 - - - - - - - - 22.2 
25 47.8 22.2 22.2 5.6 44.4 - - - - - - 5.6 
26 73.2 77.8 - 11.1 - - - 11.1  - - 0.0 
27 94.1 72.2 27.8 - - - - - - - - 0.0 
28 82.9 61.1 - 22.2 - - - - - - - 16.6 
Mean 80.6 70.0   9.7 7.4 *        
 
-, not detected 
*, the average and SD of the percentages of blue colonies responding to ato291, chis150lit135, elg01c, lab158, pep197, 
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ß-galactosidase activity in faeces and its relation to X-gal results 
 
    ß-galactosidase activity was quantified in faeces from the 12 subjects mentioned 
above.  The average enzyme activity (U/g faeces) was 22.3 ± 9.3 (mean ± SD) with 
a range of 7.4-39.2. ß-galactosidase activity in faeces was not correlated to the 
percentages of bacteria with ß-galactosidase activity, nor was it correlated to the 
percentages of Bacteroides/Prevotella, Bifidobacterium or Eubacterium 
rectale/Clostridium coccoides group. The tolerant and intolerant groups were not 
significantly different in ß-galactosidase activity (20.4 ± 5.0 vs. 25.1 ± 13.6). There 




Table 3.  The SSC, percentages and composition of colonies with ß-galactosidase activity, 
and ß-galactosidase activity in faeces of the lactose tolerant and intolerant groups (mean ± 
SD) 










tolerant 7 0.3±0.8 80.3±7.4 76.2±20.7 13.5±14.3 3.2±6.3 20.4±5.0 
intolerant 5 6.4±3.5* 76.3±10.4 60.0±31.3 8.9±16.9 5.6±9.6 25.1±13.6 
 
§
, SSC of the second lactose challenge 
*








A number of substrates and assays are available for detection of ß-galactosidase 
activity in vivo and in vitro in microorganisms. Substrates available include ortho-
nitrophenyl-ß-D-galactoside (ONPG), X-gal, chemiluminescent and fluorescent 
substrates. ß-galactosidase activity can be assayed by the colony-lift filter assay 









reported a method to detect bacteria with ß-galactosidase activity with X-gal. 
Faecal samples were cultured on an enriched Columbia agar medium modified by 
addition of X-gal. Colonies growing on this medium with blue halos were regarded 
as bacteria which produced extra-cellular ß-galactosidase. Some of these colonies 
were sub-cultured for identification by classical biochemical and morphological 
characteristics.  
In a pilot experiments, X-gal was added to Columbia agar and Wilkins-Chalgren 
agar by spreading 80 µg of X-gal solution (20 mg/ml, in dimethylformamide) 
evenly on the agar surface. When three faecal samples were cultured on these two 
modified agars, however, more than 90% of the blue colonies (with or without 
halos) were identified with FISH to be Bifidobacterium (data not shown). We 
assumed that the modified media in some way favoured the growth of 
Bifidobacterium, which did not reflect the true conditions in the faeces. Therefore, 
in our subsequent experiment, the faecal samples were first cultured on BBA agar 
medium without X-gal added and subsequently the ß-galactosidase activity was 
assayed by transferring the colonies to a filter followed by identification by FISH. 
This colony-lift filter method has been used to assay ß-galactosidase activity in 
yeasts (10). Its principle should also be applicable to bacteria and when combined 
with FISH, it would be an easy and efficient method to differentiate and identify 
bacteria with ß-galactosidase activity.  
 When the method was applied to the faecal samples from 28 subjects with 
genetically determined low lactase activity, on average 80.6% (SD: 12.1; range: 
47.8 %-100%) of the total cultured bacteria were found to possess ß-galactosidase 
activity. This is higher than what was reported by Favier et al. (57% ± 29) (11), 
which might be explained by the fact that the colonies without halos which are 
supposed to produce intra-cellular ß-galactosidase were included in our but not in 
their counting. However, it is not known yet whether the percentage of bacteria 
with ß-galactosidase activity would be influenced by maldigested lactose entering 
the colon. Our results indicate that a major part of the colonic microbiota is capable 
of hydrolyzing lactose, which is in accordance with what was described earlier (6). 
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    Strains from each of the bacterial groups identified in our experiment to be ß-
galactosidase producers were reported previously to possess this enzyme activity 
(6,13). In the study by Favier et al. (11), the blue colonies identified by culturing 
belonged to 3 groups: Bacteroides, Prevotella and Bifidobacterium. In our 
experiment, 7other groups besides 3 three groups, i.e. Atopobium group, 
Streptococcus/Lactococcus and Lactobacillus/Enterococcus, Clostridium 
histolyticum/lituseburense group, Eubacterium low G+C2, Peptostreptococcus and 
Ruminococcus group, were identified with FISH to possess ß-galactosidase activity. 
For the last few years, the FISH technique has been employed to identify and 
quantify colonic microbiota (7,14). In our study, FISH was shown to be an easy 
and efficient way to identify a large number of ß-galactosidase-producing colonies. 
During method development, 60 white colonies were also picked up randomly 
from cultures of three faecal samples on Columbia, Wilkins-Chalgren or BBA agar 
with X-gal. When hybridized with group-specific probes targeting 
Bacteroides/Prevotella, Bifidobacterium and Eubacterium rectale/Clostridium 
coccoides group, eight of them were identified as belonging to Eubacterium 
rectale/Clostridium coccoides group, three as Bacteroides/Prevotella, but none as 
Bifidobacterium (data not shown). 
    There has been discussions of the advantages and disvantages of using faeces to 
study the composition and activities of  the colonic microbiota. Some studies found 
that the bacteria in faeces reflect the microbiota in the colon (15) while other 
studies did not (16). The metabolic activities measured in faeces can be quite 
different from in the proximal colon where there is active fermentation of 
carbohydrates by bacteria. For comparing lactose-fermenting capacities and 
composition of the colonic microbiota among lactose maldigesters and also 
considering difficulties in sampling in the colon, we consider faecal samples as a 
reasonable alternative. Some studies found that carbohydrate fermentation 
properties of faecal bacteria are individual-dependent and rather stable through 
time (17,18). 
The results of measurement of bacteria with ß-galactosidase activity were 
analyzed in relation to lactose intolerant symptoms. Considering the fact that 









bias in scoring of symptoms possibly caused by familiarization with the test 
procedures or placebo effect (19), a placebo control (glucose) was included besides 
two lactose challenges in an attempt to reliably define groups of lactose tolerance 
and intolerance. A tolerant (n=7) and an intolerant (n=5) group were defined. The 2 
groups did not differ, in either the percentages or in the composition of the bacteria 
with ß-galactosidase activity in faeces. For these 12 subjects, there is no significant 
correlation between SSC and percentages of ß-galactosidase-producing colonies, or 
the percentages of Bacteroides/Prevotella, Bifidobacterium and Eubacterium 
rectale/Clostridium coccoides group in the blue colonies. Therefore, our results 
suggest that the percentages and composition of bacteria with ß-galactosidase 
activity do not play a role in lactose intolerance. 
Based on the observation that a major part of the faecal microbiota is capable of 
hydrolyzing lactose, we can hardly expect that lactose itself will present a large 
osmotic threat in the colon as it should be quickly degraded by the majority of 
colonic microbiota. It is not yet known whether the subsequent processes of 
bacterial fermentation after the hydrolysis of lactose might play a role in lactose 
intolerance. Furthermore, besides the fermentation process of lactose, other colonic 
factors, such as the colonic capacity to remove fermentation products, might also 
be related to lactose intolerance. 
The large individual variations in the percentages of each bacterial group with ß-
galactosidase activity, however, might make it difficult to clarify the differences 
between the 2 groups. Large individual differences were also observed in the 
numbers of total bacteria and main groups of bacteria in faeces in one of our 
previous studies (5). 
 ß-galactosidase activity in the 12 faecal samples from both lactose tolerant and 
intolerant subjects was quantified. No correlation was observed between ß-
galactosidase activity and the percentages and composition of bacteria with ß-
galactosidase activity. The possible explanation for this could be that the enzyme 
activity may vary considerably among the lactose-fermenting bacteria. The total 
enzyme activity in faeces is determined not only by the amount but also by enzyme 
activity of the bacteria with the enzyme. No correlation was found between SSC 
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galactosidase activity increased after lactose ingestion for a period of time while 
intolerance symptoms decreased. However, whether increased ß-galactosidase 
activity played a role in the alleviation of symptoms needs further investigation. 
In conclusion, we propose a method to differentiate and identify bacteria with ß-
galactosidase activity in a complex microbiota. The method was applied to 
investigate faecal microbiota of subjects with genetically determined low lactase 
activity. The percentages and composition of bacteria with ß-galactosidase activity 
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Background: The results of our previous study suggest that besides the small 
intestinal lactase activity and transit time, colonic processing of lactose may play a 
role in lactose intolerance. We investigated whether colonic fermentation of lactose 
is correlated with lactose intolerance.  
Subjects and methods: After 28 Chinese subjects had undergone one glucose 
(placebo) and two lactose challenges, consistent lactose tolerant (n= 7) and 
intolerant (n= 5) subjects with no complaints after glucose administration were 
defined based on the 6-h symptom scores. Prior to the challenges, fecal samples 
were collected for in vitro incubation with lactose. The incubation was carried out 
in a static system under anaerobic conditions for 5 h during which samples were 
taken for measurement of short-chain fatty acids, lactate, lactose, glucose and 
galactose. Fecal bacterial composition was determined by fluorescent in situ 
hybridization.  
Results: The tolerant and intolerant groups did not differ in the rate or degree of 
hydrolysis of lactose or production of glucose and galactose. The intolerant group 
produced D- and L-lactate, acetate, propionate and butyrate significantly faster than 
the tolerant group. In the intolerant group, the amount of acetate, propionate, 
butyrate and L- lactate produced was higher than that in the tolerant group. Fecal 
bacterial composition did not differ between the two groups.  
Conclusions: The results indicate that the degree and rate of lactose hydrolysis in 
the colon does not play a role in lactose intolerance. However, after lactose is 
hydrolyzed, a faster and higher production of microbial intermediate and end 










Lactose intolerance refers to the gastrointestinal symptoms related to incomplete 
digestion of lactose. The adult-type lactase non-persistence occurring in a large part 
of the world population leads to lactose maldigestion, which in turn can , though 
not in all cases, lead to lactose intolerance. The origin of the symptoms of lactose 
intolerance is not well understood. The osmotic load caused by the undigested 
lactose cannot be regarded as the only mechanism behind the symptoms as lactose 
intolerance is poorly related to lactose maldigestion (1). This is supported by our 
recent study in which we observed that lactose intolerant subjects with mild 
symptoms or with diarrhoea did not differ in degree of lactose digestion in the 
small intestine or orocecal transit time (2). Based on these observations, we suggest 
that besides the lactose digestion capacity in the small intestine, the colonic 
processing of maldigested lactose may play a role in lactose intolerance. 
The colonic microbiota, which ferments lactose, is an important factor in the 
colonic processing of lactose. The colonic microbiota can be studied on the levels 
of composition and the metabolic activity. In our recent study in which fecal 
bacteria were quantified with fluorescent in situ hybridization (FISH), we did not 
observe significant differences in the composition of the fecal microbiota between 
lactose intolerant subjects with mild symptoms or with diarrhoea, possibly because 
of large inter-individual differences. However, there was a negative correlation 
between the total number of  bacteria and the 6-h symptom score (SSC), suggesting 
that the fermentation capacity of the colonic microbiota may be correlated to 
lactose intolerance (3). 
During colonic fermentation, lactose is first hydrolyzed to glucose and galactose, 
which are subsequently fermented, leading to the production of a series of 
intermediate (e.g. lactate, formate and succinate) and end-product metabolites (i.e. 
acetate, propionate and butyrate, gas (H2, CO2 and CH4) and biomass) (4,5). In the 
present study, we investigated whether the colonic fermentation of lactose was 
correlated to lactose intolerance by comparing the in vitro lactose-fermenting 










and rate of hydrolysis of lactose and production of lactate and short-chain fatty 
acids (SCFA) were compared between the two groups. 
 
 




Twenty-eight healthy Chinese subjects (temporarily living in The Netherlands, 16 
females and 12 males, age range 20-31 years) were recruited for this study. All 
subjects did not have diabetes or gastrointestinal disorders, and had not taken 
antibiotics or laxatives during the three months prior to the study. Every subject 
signed a declaration of informed consent. The study was approved by the Medical 
Ethical Committee of the Groningen University Hospital and Faculty of Medical 
Sciences. 
 
Collection of fecal samples 
 
The 28 subjects donated fecal samples for the in vitro fermentation experiment. 
Feces were collected in a sterile bag and maintained anaerobically with 
AnaeroGenTM COMPACT (Oxoid Limited, Hampshire, England). After arrival in 
the laboratory, samples were kept under 4 °C. All samples were processed within 2 
h after defecation. The processing procedure took about 20 min. 
 
In vitro fermentation of lactose by fecal bacteria 
 
Fecal samples were diluted five times as described previously (6), brought into an 
anaerobic chamber (Anaerobic workstation, Concept 400, West Yorkshire, UK; 
10%H2, 10%CO2, 80%N2) and further diluted two times. For each fecal sample, 20 
mL of this suspension was added to 20 mL of the anaerobic salt solution either 
with lactose (final concentration approximately: 55.6 mmol/L, or 0.4 g/ g stool 
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culture was to estimate the endogenous production of SCFA and lactate from 
carbohydrates, mucin or other substrates in the original fecal samples. Both the 
control culture and the culture with lactose were done in duplicate. In the 
incubation medium the feces were diluted 20 times. The cultures were incubated at 
37 °C under anaerobic conditions for 5 h. During the incubation, samples were 
taken from the cultures at 0, 0.5, 1, 2, 3 and 5 h for quantification of SCFA, lactate 
and sugars (lactose, glucose and galactose). For measurement of lactate, the 
samples were immediately stored at -20 °C until measurement. For measurement of 
SCFA and sugars, 1 mL of the samples was first mixed with 1.5 mL of 96% 
ethanol, centrifuged at 1500 × g  for 5 min and the supernatant was stored at -20 °C 
until analysis. 
 
Classification of lactose tolerant and intolerant subjects 
 
One to three weeks after donating fecal samples, the 28 subjects first underwent a 
challenge of 25 g glucose and a challenge of 25 g lactose in two single-blinded 
tests. SSC was recorded during the 6 h after the challenge according to the method 
described earlier (2). The purpose of the glucose challenge was to select subjects 
who did not report complaints after glucose ingestion. A SSC less than 2 was 
considered as ‘no complaints’. Among the 28 subjects, 20 reported a SSC of less 
than 2 after glucose and they underwent a second challenge of 25 g of lactose after 
which SSC was also recorded. The SSC after the glucose and the two lactose 
challenges was combined together to define subjects who were ‘truly’ lactose 
tolerant or intolerant according to the following criteria: (1) SSC  2 after glucose 
challenge; (2) consistent SSC after the two lactose challenges. Therefore, lactose 
tolerant subjects are defined as having SSC  2 after glucose and the two lactose 
challenges; while intolerant subjects are defined as having SSC  2 after glucose 
and SSC > 2 after the two lactose challenges. The SSC recorded during the second 
lactose challenge was used in the analysis of possible correlation between SSC and 











Quantification of lactate, SCFA (acetate, propionate and butyrate) and sugars 
(lactose, glucose and galactose) in the in vitro fermentation samples 
 
Of the 28 subjects, 12 were defined as lactose tolerant or intolerant according to the 
criteria mentioned above. Sugars, SCFA and lactate were quantified in the in vitro 
fermentation samples of these 12 subjects. Sugars were determined by gas 
chromatography by the method of Jansen et al. (7) with a few modifications, i.e. 
before derivatization, after methanol was added to the samples and the internal 
standard, the solution was directly evaporated to dryness without other processing 
steps; after derivatization, heptane was used for extraction instead of hexane; for 
gas chromatography analysis, GC-MS was used instead of GC, 1 µL was injected 
instead of 2 µL. The L- and D-lactate were quantified by an enzymatic method 
using EnzytecTM L- and D-lactate kits (Scil Diagnostics GmbH, Viernheim, 
Germany). For measurement of SCFA, 50 µL 15 mmol/L iso-butyrate in water 
(internal standard), 100 µL of the sample or  SCFA standards (0 – 2 µmol)/ 96% 
ethanol (1:1.5, v/v) and 900 µL 96% ethanol / water (3:2, v/v) were added to a 
headspace vial. 100 µL 96% H2SO4 was added for acidification. The vials were 
stored at room temperature until analysis. The analysis is based on headspace gas 
chromatography (GC). The SCFA were separated on a WCOT fused silica 25m x 
0.32 mm ID 0.2 mm Poraplot Q column (Varian, Middelburg, The Netherlands) 
using an Agilent 6890 GC (Agilent technologies, Amstelveen, The Netherlands). 
The flow rate was kept constant at 1.1 mL/min. The temperature programme was 
as follows: initial temperature 100oC; 10o/min to 150oC; 7.5o/min to 250oC. The gas 
phase sample was injected in the splitless mode using a 1 mL loop injection system. 
The injection temperature and flame ionization detector temperature were 250oC. 
The headspace device was an Agilent 7694 headspace sampler. The headspace 
conditions were as follows: headspace temperature 90oC, loop temperature 95oC, 
tray line 100oC, vial equilibration time 15 min, pressurizing time 3.0 min, loop fill 
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Quantification of bacteria in feces with fluorescent in situ hybridization (FISH) 
 
16S rRNA oligonucleotide probes were used to detect the numbers of total bacteria 
and major bacterial groups in the fecal samples from the 12 lactose tolerant and 
intolerant subjects (Table 1). With this set of probes, more than 90% of the total 
bacterial cells in the feces of adults could be detected (8,9). The hybridization and 
visualization of fluorescent cells were carried out according to the methods 
described previously (8,10). 4’, 6-diamidino-2-phenylindole (DAPI)-staining was 
used to enumerate the total amount of cells in feces (10). 
 
 Normalization of the data with the number of total bacteria 
 
As the amount of fecal sample used for incubation was determined by wet weight, 
it was possible that for different samples, different numbers of bacteria were added 
to the incubations. Therefore, the in vitro fermentation data were normalized to the 




Data are expressed as mean ± SD. Logarithmic transformation of the data was 
performed when necessary to obtain normally distributed data and when the data 
stayed skewed after logarithmic transformation, nonparametric tests were applied. 
The hydrolysis rates of lactose and the production rates of SCFA, lactate, glucose 
and galactose were calculated for periods within 0-0.5, 0.5-1, 1-2, 2-3 and 3-5 h of 
incubation (Table 2). The slope of the curve between two sampling points was 
calculated and taken as the rate of the time period. The slope of the curve between 
0-5 h was calculated and taken as the overall rate. As the rate of fermentation 
during different periods of incubation can differ among subjects, which might be 
correlated with the occurrence of symptoms, comparison between the tolerant and 
intolerant groups took all the rates or concentrations of metabolites of different 
periods into consideration. The Univariate test was applied to assess the overall 










hydrolysis and production, and the overall differences in the concentrations of 
sugars, SCFA and lactate at 0, 0.5, 1, 2, 3 and 5h. The Student t-test (unpaired, 
two-tailed), the Mann-Whitney U-test and the Multivariate test were applied to 
assess the difference between the two groups in numbers of total cells (DAPI), total 
bacteria (Eub338) and major bacterial groups in feces (Bac303, Erec482, Fprau645, 
Bif164y, Ato291 and Rbro729/Rfla730), respectively. Correlations were assessed 
by calculating the Spearman correlation coefficients. P < 0.05 was regarded as 
significant. All analyses were performed using SPSS 12.0 for Windows software 
(SPSS Inc., Chicago, IL, USA).  
 
Results 
     
Classification of lactose tolerant and intolerant subjects 
After the 28 subjects had undergone one glucose and two lactose challenges, 12 
subjects were defined as lactose intolerant (n=5) or tolerant (n=7) according to the 
following criteria: (1) SSC  2 after glucose challenge; (2) consistent SSC after the 
two lactose challenges; (3) tolerant when SSC  2 and intolerant when SSC > 2. 
 
Hydrolysis of lactose 
During the 5 h incubation, the tolerant and intolerant groups did not differ in the 
hydrolysis rates of lactose (P >0.1) or the production rates of glucose (P >0.1) and 
galactose (P = 0.09) (Table 2), or in the concentrations of lactose (Fig. 1), glucose 























Figure 1. In vitro hydrolysis 
of lactose by fecal bacteria 
from lactose tolerant (n=7) 
and intolerant (n=5) subjects. 
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Production of SCFA 
 
The amounts of SCFA produced in the control cultures were subtracted from those 
in the cultures with lactose. During the 5 h incubation, the production rates of 
acetate (P = 0.05), propionate (P < 0.01) and butyrate (P = 0.03) were higher in the 
intolerant group than in the tolerant group (Table 2). The intolerant group produced 
more acetate(P = 0.03), propionate (P < 0.01) and butyrate (P < 0.01) than the 
tolerant group (Fig. 2). At 5 h, the ratios of acetate, propionate and butyrate were 
6:1:1 and 4:1:1 for the tolerant and intolerant group, respectively. The 
concentrations of the three SCFA at 5 h was not different between the two groups 
(P > 0.1). 
 
Table 2. In vitro hydrolysis rates of lactose and production rates of glucose, galactose, 
SCFA and lactate during incubation of fecal bacteria from lactose tolerant and 
intolerant subjects1. 
 
Time after inoculation, h 
Compound    Subjects 0-0.5 0.5-1 1-2  2-3 3-5 0-5 
   mmolL-1h-1   
Lactose         tolerant 
                    intolerant 
5.1 ± 5.9 
2.4 ± 5.5 
8.1 ± 7.7 
5.2 ± 6.1 
3.1 ± 5.2 
8.2 ± 6.4 
7.0 ± 2.9 
5.4 ± 1.8 
4.6 ± 1.8 
4.9 ± 2.7 
5.2 ± 2.1 
5.7 ± 3.0 
Glucose        tolerant 
                    intolerant 
 0.2 ± 0.2 
 0.1 ± 0.1 
 0.4 ± 0.5 
 0.4 ± 0.5 
 0.6 ± 0.9 
 1.0 ± 1.0 
 0.4 ± 0.7 
 -0.1 ± 0.8 
 0.8 ± 0.9 
 0.4 ± 1.5 
0.5 ± 0.6 
0.4 ± 0.2 
Galactose     tolerant 
                    intolerant 
 0.3 ± 0.3 
 0.1 ± 0.1 
 0.4 ± 0.5 
 0.2 ± 0.2 
 0.9 ± 0.9 
 0.7 ± 0.6 
 0.9 ± 0.8 
 0.8 ± 0.7 
 2.4 ± 0.8 
 1.6 ± 0.8 
1.0 ± 0.7 
0.7 ± 0.5 
Acetate         tolerant 
                    intolerant 
 0.9 ± 0.9 
 2.9 ± 2.5* 
 2.8 ± 2.5 
 5.0 ± 2.9* 
 4.1 ± 3.6 
 6.4 ± 3.4* 
 4.1 ± 2.2 
 4.3 ± 2.0* 
 2.7 ± 2.0 
 3.5 ± 1.9* 
3.3 ± 2.0 
4.5 ± 2.1 
Propionate    tolerant 
                    intolerant 
 0.2 ± 0.3 
 0.7 ± 0.8* 
 0.3 ± 0.6 
 0.9 ± 1.0* 
 0.7 ± 0.8 
 1.4 ± 1.6* 
 0.8 ± 1.1 
 1.1 ± 0.9* 
 0.5 ± 0.6 
 1.2 ± 1.0* 
0.6 ± 0.6 
1.2 ± 1.0 
Butyrate       tolerant 
                    intolerant 
 0.0 ± 0.1 
 0.2 ± 0.2* 
 0.2 ± 0.2 
 0.4 ± 0.3* 
 0.5 ± 0.6 
 1.4 ± 0.9* 
 0.6 ± 0.7 
 1.1 ± 0.6* 
 1.1 ± 1.5 
 2.3 ± 1.4* 
0.5 ± 0.6 
1.1 ± 0.6 
L-lactate       tolerant 
                    intolerant 
 0.1 ± 0.1 
 0.2 ± 0.1* 
 0.3 ± 0.5 
 0.5 ± 0.2* 
 0.8 ± 1.0 
 2.2 ± 1.6* 
 1.5 ± 2.9 
 1.1 ± 1.3* 
 1.3 ± 0.5 
 1.6 ± 2.1* 
0.9 ± 1.1 
1.2 ± 0.5 
D-lactate      tolerant 
                    intolerant 
 0.0 ± 0.1 
 0.3 ± 0.1* 
 0.2 ± 0.4 
 0.4 ± 0.2* 
 0.3 ± 0.3 
 0.7 ± 0.6* 
 0.7 ± 1.0 
 0.9 ± 0.7* 
 0.7 ± 0.4 
 1.2 ± 1.3* 
0.5 ± 0.4 
0.9 ± 0.6 
 
1 
 Values are means ± SD, n=5 (intolerant) or 7 (tolerant). * Different overall (taking all 5 






















































































Figure 2. In vitro production of acetate (A), propionate (B) and butyrate (C) by fecal 
bacteria from lactose tolerant (n = 7) and intolerant (n = 5) subjects. Values are means +/- 
SD. The intolerant group differed overall (taking all 6 time points together) from the 
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Production of L- and D-lactate 
As the concentrations of L- and D-lactate after 5 h of incubation were relatively 
low in the control culture ( 0.4 ± 0.3, 0.5 ± 0.5 mmol/L, respectively), the amounts 
of L- and D-lactate produced in the control cultures were not subtracted from those 
in the cultures with lactose. During the 5 h incubation, the production rates of L- (P 
< 0.01) and D-lactate (P = 0.03) were higher in the intolerant group than in the 
tolerant group (Table 2). The intolerant group produced more L-lactate than the 
tolerant group (P < 0.01; Fig. 3). At 5 h, the ratio between D- and L-lactate was 
1:1.5 and 1:1.4 for the tolerant and intolerant group, respectively. The 
concentrations of D- and L-lactate at 5 h was not different between the two groups 















































Figure 3. In vitro production of D-lactate (A) and L-lactate (B) by fecal bacteria from 
lactose tolerant (n = 7) and intolerant (n = 5) subjects. Values are means +/- SD. (B) The 
intolerant group differed overall (taking all 6 time points together) from the tolerant group 










Composition of bacteria in feces 
The tolerant and intolerant group did not differ in the numbers of total cells, total 
bacteria or the major bacterial groups (Table 1). The numbers of total bacteria or 
each bacterial group were not correlated with SSC (data not shown). 
 
Normalization of the data to the number of total bacteria 
After normalization, the results of the comparison between the two groups stayed 
the same except that the tolerant group produced more galactose (P = 0.01) more 
rapidly (P = 0.05) than the intolerant group (data not shown). 
 
 
Table 1. Bacteria in feces from lactose tolerant and intolerant subjects quantified by FISH1. 
 
  Intolerant  Tolerant 
Stain or probes Targeted groups Cells (1010) 2   %total bacteria3  Cells (1010) 2  %total bacteria3 
DAPI Total cells 21.0± 10                  129.2   17.0± 16                146.9  
Eub338 Bacteria 16.0 ± 6.4                100  11.0 ± 9.1              100 
Bac303 Bacteroides/Prevotella   4.8 ± 2.2                  34.6    2.9 ± 2.6                31.7 
Erec482 Eubacterium rectale/Clostridium 
coccoides group 
  4.3 ± 2.7                  24.2    2.2 ± 2.5                16.9 
Rbro729/Rfla730 Ruminococcus group   2.0 ± 1.2                  10.9    1.8 ± 1.9                13.4 
Fprau645 Fecalibacterium   1.5 ± 1.0                    9.2    1.1 ± 1.1                  9.3 
Bif164y Bifidobacterium   1.0 ± 1.1                    5.2    0.7 ± 0.5                11.6 
Ecyl1387 Eubacterium cylindroides group   0.2 ± 0.4                    1.0     0.01 ± 0.02              0.4 
Ato291 Atopobium group   0.09 ± 0.07                0.5    0.07 ± 0.1                1.4 
Strc493 Streptococcus/Lactococcus   0.09 ± 0.11                0.5    0.04 ± 0.05              0.4 
Ec1531 Enterobacteriaceae   0.02 ± 0.04                0.1    0.01 ± 0.01              0.2 
Lab158 Lactobacillus/Enterococcus   0.003 ± 0.006            0.02    0.001 ± 0.001          0.01 
Chis/Clit Clostridium histolyticum / 
lituseburense group 
  0.002 ± 0.002            0.01    0.001 ± 0.001          0.004 
Phasco741 Phascolarctobacterium group nd4  nd 
Veil223 Veillonella nd  nd 
 
1
 Values are means ± SD or %, n=5 (intolerant) or 7 (tolerant). 
2
 per g feces, dry weight 
3Percentage of Bacteria (Eub338). 










In the present study, in vitro incubation with lactose showed that the fecal 
microbiota from lactose intolerant subjects had faster production rates of D- and L-
lactate, acetate, propionate and butyrate than that from the tolerant subjects. The 
amounts of L-lactate and SCFA (acetate, propionate and butyrate) produced were 
higher in the intolerant subjects than the tolerant subjects. The rate or degree of the 
hydrolysis of lactose was not different between the two groups. 
Whether colonic fermentation of lactose would influence the occurrence of 
lactose intolerance, either aggravate or alleviate it, depends on the balance between 
the ability of the colonic microbiota to ferment lactose and the ability of the colon 
to remove the fermentation metabolites. A low lactose-fermenting capacity of the 
colonic microbiota, which leads to inefficient removal of the maldigested lactose 
(and/or its intermediate fermentation metabolites), or a low absorption capacity of 
the colon which leads to inefficient removal of the fermentation metabolites, may 
contribute to the occurrence of symptoms. When lactose is converted to SCFA by 
fermentation, the osmotic load is increased by about eight fold, which makes the 
efficiency of the colon to absorb these fermentation metabolites an important 
determinant for the outcome of the osmotic load caused by malabsorbed lactose 
(11). It is generally believed that the colon has a high capacity to absorb SCFA 
(12,13), the absorption rate is 6.1-12.6 µmmol/(cm2.d) (14,15). However, there are 
differences among segments in colonic permeability for the three major SCFA. 
Acetate is absorbed at the highest rate in the cecum and proximal colon, and 
butyrate in the distal colon; propionate is absorbed at a similar rate in the proximal 
and distal colon (16). Lactate is an intermediary organic acid in the bacterial 
fermentation of carbohydrates and is further converted to SCFA and as a result, it 
is rarely present in large amounts in feces (15,17,18). If the colon can absorb SCFA 
at a sufficient rate, a higher lactose-fermenting capacity of the colonic microbiota 
may help to alleviate lactose intolerance. 
However, our results do not support this assumption. A possible explanation for 
our observations could be that although the colon is thought to possess a high 










short period in situ all the SCFA produced from rapid fermentation of lactose. 
Several studies reported increased cecal SCFA pools or lactate concentration in rats 
fed oligosaccharides or fructo-oligosaccharides, indicating colonic accumulation of 
organic acids produced from rapid fermentation of those carbohydrates (19-21).  
Accordingly, the rapid fermentation of undigested lactose may result in temporary 
accumulation of SCFA in the lumen, which causes symptoms. Lactate and other 
intermediate metabolites can also accumulate temporarily if their further 
conversion and absorption by the colon cannot counteract their production. 
Segmental differences existing in colonic absorption rates of SCFA might play a 
role in accumulation of SCFA in certain parts of the colon. For instance, the 
absorption rate of butyrate is lower in the cecum and proximal colon (16) which is 
a major site of carbohydrate fermentation. Therefore, fermentation of lactose might 
lead to accumulation of butyrate in this part of the colon. In the present study, we 
observed that the production rate of butyrate in vitro was faster in lactose intolerant 
subjects than tolerant subjects.  
    Several hypotheses may explain why the temporarily accumulated fermentation 
metabolites could cause symptoms. Firstly, the osmotic load posed by those 
temporarily accumulated metabolites will draw fluid to the colonic lumen. The 12 
lactose tolerant and intolerant subjects digested 38±12% of the 25 g lactose in the 
small intestine (data not shown) as estimated by the lactose digestion index (22). In 
principle, colonic fermentation converts 1 mol of lactose to about 3.7 mol of 
organic acids (23), but in real situation the production will be less as a considerable 
part of hexose will be incorporated into bacterial mass (24). The malabsorbed 
lactose (25 g × 60% = 15 g), which we assume is completely converted to organic 
acids, represents an osmotic load of ~ 190 mOsm, which will result in 633 mL of 
water in the colon (11).  But this amount of fluid is unlikely to cause symptoms 
considering the high capacity of the colon to absorb fluid (25). Secondly, 
symptoms could appear because of the altered intestinal motility. The temporarily 
accumulated fermentation metabolites could trigger motor events of the intestine. 
Colonic fermentation of undigestible carbohydrates or/and its products are 
regarded to affect the motility of  the proximal part of the gastrointestinal tract (26-
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also affect motility of the upper gut. The motor effects of SCFA are dose-
dependent, suggesting that excessive amounts of rapidly- fermented sugars might 
induce undesirable motor and sensitive effects. However, those effects of SCFA 
are not observed yet in humans (33). Furthermore, chemosensitive intestinal 
receptors, e.g. glucoreceptors, acid and alkali receptors, are present in the stomach 
and the small intestine (34). It is not known whether chemosensitive receptors are 
also present in the colon and if so, whether they will respond by altering the 
motility of the intestine upon chemical stimulation of fermentation metabolites. 
Alterations in motility of gastrointestinal tract are believed to play an important 
role in the origin of symptoms in the functional gastrointestinal disorders (35,36), 
the symptoms of which resemble those of lactose intolerance. It is not clear 
whether changes in intestinal motility are correlated to symptoms of lactose 
intolerance. Jouet et al. found that only 37% of the symptoms after intake of 40 g 
lactulose coincided in time with colonic motor events (37). Moreover, the 
temporarily accumulated fermentation metabolites can cause colonic 
hypersensitivity.  In two recent studies, butyrate enemas elicited colonic 
hypersensitivity in rats (38) and was used to develop a model of chronic colonic 
hypersensitivity as a tool for studying irritable bowel syndrome (39). 
The hydrolysis of lactose to glucose and galactose is the first step of colonic 
fermentation of lactose, catalyzed by the enzyme ß-galactosidase. ß-galactosidase 
is often measured as an indicator of the colonic capacity to ferment lactose (40-42). 
However, we have recently observed that the majority (80.6%) of the fecal 
microbiota from lactase non-persistent subjects possesses ß-galactosidase activity 
(6). It is unlikely that lactose itself will present a large osmotic threat in the colon 
as it should be quickly hydrolyzed by the colonic microbiota. Results from the 
present study are in agreement with this assumption. There were no differences in 
the hydrolysis of lactose between the lactose tolerant and intolerant subjects in the 
in vitro incubation. Based on the above observation, we conclude that the 
hydrolysis of lactose does not play a role in lactose intolerance. Instead, the 
fermentation steps following the hydrolysis of lactose are related to the 










    Similar to what we found in a previous study (3), the composition of fecal 
microbiota was not different between the lactose tolerant and intolerant subjects. 
The possible reasons why differences in the fecal microbiota between the two 
groups were found in metabolic activities but not in composition could be that the 
detection of bacteria with FISH is not based on a strain-specific but a genus- or 
group-specific level. Bacterial strains of the same genus or group may have 
different metabolic capacities. Furthermore, the detection limit of bacteria in feces 
with FISH is about 106–107cells/g feces (0.001-0.01% of the total fecal bacteria). 
Bacterial groups with amounts below this level cannot be detected with FISH. In 
addition, large variations in bacterial numbers among individuals are often reported 
(3,8), which makes it difficult to clarify the differences in bacterial composition.  
Feces are often used in studies on fermentation properties of the colon, 
considering the difficulties to sample directly in the colon and the observations that 
the indices of in vitro incubation with feces can be used to predict or interpret in 
vivo conditions and are rather stable through time and individual-dependent (43-46). 
However, there might be differences between metabolic activities determined with 
in vitro fermentation of fecal bacteria and that present in the colon, especially the 
cecum and proximal colon which is the major site of carbohydrate fermentation. In 
vivo studies, e.g. those in which stable isotope techniques are applied (47), may 
help to shed more light on colonic fermentation of carbohydrates. 
    In summary, by comparing the in vitro lactose-fermenting indices of fecal 
bacteria from lactose tolerant and intolerant subjects, we suggest that the colonic 
fermentation of lactose by the microbiota plays a role in lactose intolerance. The 
fermentative processes after lactose is hydrolyzed are related to the development of 
symptoms, while the hydrolysis of lactose is not. Studies are needed to further 
investigate the mechanisms by which those fermentative processes following 
hydrolysis of lactose and the intermediate and end metabolites of those processes 
influence the development of symptoms. Furthermore, the reaction of the colon 
towards those metabolites, i.e. absorption rate and motility alterations, ought to be 
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Background: Colonic metabolism of lactose, in addition to the small-intestinal 
lactase activity and transit time, may play a role in lactose intolerance. We 
investigated whether supplementation of yogurt and bifidobacteria could modify 
the colonic microbiota and influence the symptom response in lactose intolerant 
subjects. 
Subjects and methods: Eleven Chinese lactose intolerant subjects consumed a 
yogurt enriched with Bifidobacterium animalis and capsules with Bifidobacterium 
longum for two weeks. The total number of bacteria and major bacterial groups in 
faeces were quantified with fluorescent in situ hybridization. PCR-denaturing 
gradient gel electrophoresis was used to study dynamics of the faecal 
bifidobacterial population. The subjects received oral challenges of 25 g of lactose 
one day before and one day after the supplementation period, during which blood 
samples were collected for measurement of the degree of lactose digestion in the 
small intestine (indicated by lactose digestion index, LDI) and a 6-h symptom 
score (SSC) was recorded. 
Results: The numbers of total cells, total bacteria and the Eubacterium 
rectale/Clostridium coccoides group, and faecal ß-galactosidase activity increased 
significantly during the supplementation period. The number of Bifdobacterium 
showed a tendency to increase during and after supplementation. The percentages 
of the major bacterial groups remained similar throughout the study. LDI was not 
different before and after supplementation, whereas SSC decreased after 
supplementation. The bifidobacterial strain in the yogurt was present in faeces 
during supplementation, but disappeared after consumption had stopped. 
Conclusions: The results suggest that supplementation of yogurt and bifidobacteria 
modifies the amount and metabolic activities of the colonic microbiota, but does 
not increase the endogenous lactase activity in the small intestine. The changes in 
the colonic microbiota might be among the factors modified by the 










Besides the amount of lactose ingested, and the small-intestinal lactase activity and 
transit time, colonic processing of lactose (1,2), especially the fermentation of 
lactose by the colonic microbiota (3), may affect the occurrence of symptoms of 
lactose intolerance. Therefore, it can be hypothesized that modulating the 
composition and/or metabolism of the colonic microbiota may influence lactose 
intolerance. Modulation of the colonic microbiota may be achieved through the 
targeted use of dietary supplementation, i.e. probiotics, prebiotics and synbiotics 
(4). 
In several reviews (5-8), some probiotics are regarded to be able to improve 
lactose digestion and eliminate symptoms of intolerance. The mechanisms by 
which these probiotics exert their effects are not fully understood yet, but may 
involve modifying gut pH, providing ß-galactosidase, exerting positive effects on 
intestinal functions and colonic microbiota. However, in a systematic review by 
Levri et al (9), it was concluded that probiotic supplementation in general did not 
alleviate the symptoms of lactose intolerance in adults. Bifidobacterium spp., 
together with Lactobacillus spp., are the bacteria most applied as probiotics 
because of their potential health benefits (10,11). 
Yogurt is defined by the Codex Alimentarius of 1992 as a coagulated milk 
product that results from the fermentation of lactose in milk by Lactobacillus 
bulgaricus and Streptococcus thermophilus (12). Some lactic acid bacteria can be 
combined with yogurt starters for their probiotic properties. In addition to the 
effects of yogurt-derived microbial ß-galactosidase, yogurts improve lactose 
digestion and tolerance by delaying gastric emptying, oro-cecal transit time, or 
both (6). The lactose contained in yogurts can be considered as a prebiotic for 
people with lactose maldigestion (13,14). Regular consumption of lactose 
influences their colonic microbiota (15,16) and reduces lactose intolerance (17).  
Supplementation of yogurt and/or probiotics modified the composition and 
metabolism of the colonic microbiota in healthy adults (18,19), healthy infants (20) 
and patients with functional bowel disorders (21). In those studies, enumeration of 









very accurate picture of the composition of the colonic microbiota as not all 
bacteria can be cultured and media are not always specific (22). 
    The subjects for this study were selected from a group of Chinese lactose 
maldigesters based on their high symptom scores in lactose challenge tests. Those 
Chinese maldigestors harbored considerably less Bifidobacterium (23) in their 
colon than European subjects (24). The objective of this study was to investigate 
the effects of supplementation of a yogurt enriched with Bifidobacterium animalis 
and capsules with Bifidobacterium longum on the colonic microbiota and on 
symptom response in lactose intolerant subjects. Molecular techniques were 
applied to detect and quantify bacteria in faeces. We also investigated whether the 
supplementation would increase the endogenous lactase activity in the brush border 
of the small intestine. The design of the study does not include the instant effect of 
yogurt on hydrolysis of lactose in the small intestine. 
 
 




Eleven healthy Chinese subjects (5 males and 6 females, age range 23-54 years) 
were recruited for this study. The subjects were selected from a group of lactose 
maldigesters based on their high 6-h symptom scores (>10) in oral lactose 
challenge (25 g lactose in water) tests in the year previous to the study. The 
subjects had not taken antibiotics or laxatives during the three months prior to the 
study. The subjects were asked to keep their habitual diet throughout the study 
period. All subjects gave a verbal informed consent. The study was approved by 
the Medical Ethical Committee of the Groningen University Hospital and Faculty 
of Medical Sciences, Groningen, The Netherlands, and of the West China 









 Yogurt and bifidobacteria supplementation in lactose intolerant subjects 
 121 
Yogurt and bifidobacteria supplementation 
 
The yogurt used in this study was a fermented milk with the traditional yogurt 
strains (Lactobacillus bulgaricus and Streptococcus thermophilus) and a specific 
starter: Bifidobacterium animalis DN-173010 (approximately 108 colony forming 
units (CFU) per g of product) (Danone, Shanghai, China). The probiotic 
administered was encapsulated Bifidobacterium longum (Bifina®, Morishita Jintan 
Co. Ltd., Osaka, Japan), each capsule contained 2 × 108 CFU freeze-dried 




The study was divided into three periods (Figure 1): a 1-w baseline period, a 2-w 
supplementation period, and a 1-w follow-up period. During the supplementation 
period, each subject consumed per day three times three Bifina® capsules and three 
times 125g of yogurt. 
Faecal samples were collected for analysis of composition of the faecal 
microbiota and ß-galactosidase activity. In total five faecal samples were collected: 
two in the baseline period, two in the supplement period, and one in the follow-up 
period. Faeces was collected in a sterile bag, kept at 4 °C after arrival in the 
laboratory, and processed within 12 h after collection. 
 Two oral lactose challenge tests (25 g of lactose in water) were carried out: one 
day before and one day after the supplement period. A 6-h symptom score (SSC) 
was recorded as described earlier (2) and blood samples were collected for 
measurement of the lactose digestion index (LDI ). LDI was determined with the 
13C/2H-glucose test as described previously (25) with a slight modification: blood 
samples were collected before ingestion of lactose, 45 and 60 min after ingestion of 
lactose. LDI was calculated as the mean value of the two samples collected at 45 
and 60 min.  
SSC was also recorded in these 10 subjects after a lactose challenge in the year 










Quantification of bacteria in faeces with fluorescent in situ hybridization 
(FISH) 
 
16S rRNA oligonucleotide probes were used to detect the numbers of total bacteria 
and predominant bacterial groups in the faecal samples (Table 1). The 
hybridization and visualization of fluorescent cells were carried out according to 
the methods described previously (24,24,26,26). The detection limit of bacteria in 
faeces with our FISH technique is about 106–107cells/g faeces (0.001-0.01% of the 
total faecal bacteria). In addition to FISH, 4’, 6-diamidino-2-phenylindole (DAPI)-
staining was used to enumerate the total amount of cells in faeces (26). 
 
Analysis of the bifidobacterial population in faeces with PCR-denaturing 
gradient gel electrophoresis (PCR-DGGE) 
 
DNA extraction and PCR.  
0.5 g of each stool was suspended in 4.5 ml filtered PBS and homogenized on a 
vortex for 3 min together with a few glass beads (diameter, 4 mm). The suspension 
was centrifuged at 700 × g for 1 min, then 1 ml of the supernatant was centrifuged 
again at 14000 × g for 5 min. The pellet was stored at -20 °C until DNA extraction. 
Total DNA was extracted as described previously (27).  
 The DNA was diluted 100-fold for PCR amplification. The forward primer U515 
(5'-GTGCCAGCAGCCGCGGT-3') and Bifidobacterium genus-specific reverse 
primer 1412 (lm3, 5'-CGGGTGCTICCCACTTTCATG-3') (28) were used for 
amplification of the 16S rRNA gene of Bifidobacterium. The reaction mixture 
(50µl) consisted of reaction buffer (final concentrations, 15 mmol/L Tris-HCl (pH 
8.0), 50 mmol/L KCl, 0.01% (v/v) Tween 20), 2.5 mmol/L MgCl2, 1.6 mmol/L of 
each deoxynucleoside triphosphate, 200 nmol/L of each primer, 2.5 U Hot Goldstar 
Taq polymerase (Eurogentec, Seraing, Belgium), and 1 µl 100-fold diluted 
template DNA. The PCR was performed in a T-gradient thermocycler (Biometra, 
Göttingen, Germany) using the following conditions: 95°C for 10 min; 34 cycles of
 95°C for 45s, 50°C for 2 min and 72°C for 2min; finally 72°C for 5min. The 
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resulting amplicons were diluted 1000-fold and used as template for a second PCR. 
Forward U968-GC(5'-GCCCGGGGCGCGCCCCGGGCGGGGCGGGGGCACGG 
GGGGAACGCGAAGAACCTTAC-3') and reverse U1406 (5'-ACGGGCGGTGT 
GTRC-3') primers (29) were used to amplify the V6 – V8 regions of bacterial 16S 
rRNA gene. The PCR conditions were as follows: 95°C for 10 min; 25 cycles of 
95°C for 30s, 56°C for 1 min and 72°C for 1 min; finally 72°C for 5 min. The PCR 
amplicons were checked for their size by electrophoresis on agarose (10 g/L) gel 
containing ethidium bromide. 
 
Bifidobacterium markers 
DNA fragments of bifidobacterial strains. in the yogurt and Bifina® capsules, and 
mixed DNA fragments of 6 bifidobacterial strains were prepared as markers for 
DGGE. The 6 bifidobacterial strains included: B. adolescentis, B. bifidum, B. 
breve, B. dentum, B. longum and B. pseudo longum. Each bacterial strain was 
cultured on Brucella blood agar (BBA) under anaerobic conditions at 37°C. The B. 
animalis in the yogurt and B. longum in Bifina® capsules were obtained by 
culturing the yogurt and capsules on BBA, followed by re-culturing a colony which 
hybridized with the 16S rRNA-based probe Bif164y (30). Sequence analysis 
confirmed that the strain obtained from the yogurt was a B. animalis subspecies 
lactis. DNA extraction of the bacterial colonies and PCR amplification were 
performed as mentioned above. PCR amplicons of the 6 strains were mixed 
together to make a combined marker. 
 
DGGE analysis 
 Polyacrylamide gels (9% [w/v] acrylamide-bisacrylamide [37.5:1]) in 20 mmol/L 
Tris-acetate-EDTA buffer (pH7.4) with a denaturing gradient were prepared with a 
gradient mixer. The gel contained a 45 to 70% gradient of urea and formamide 
increasing in the direction of electrophoresis. A 100% denaturing solution 
contained 40% (v/v) formamide and 7.0 mol/L urea. The PCR amplicons were 
loaded on the gel and separated by electrophoresis in a PhorU system apparatus 
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for 16h. After electrophoresis, the gel was silver-stained as described previously 
(31). 
 
Quantification of ß-galactosidase activity in faeces 
 
An aliquot of 0.5 g of each stool was kept at -20°C until the measurement of ß-
galactosidase activity. The 0.5 g of stool was diluted with 4.5ml buffer (0.02 mol/L 
Na2HPO4, 0.01 mol/L MgSO4, 0.001 mol/L dithiothreitol, pH 7.0) and 0.5 ml of 
this suspension was sonicated on ice (4 × 1 min with 15 s intervals) with a 
Soniprep 150 (Beun de Ronde BV, Abcoude, the Netherlands) followed by 
centrifugation (16100 × g, 10 min). The ß-galactosidase activity in the supernatant 
was measured by determining the hydrolysis of p-nitrophenyl-ß-D-




 Data are expressed as mean ± SD. For statistical evaluation of FISH and ß-
galactosidase results, the results for baseline and supplementation periods were the 
average of the two samples taken in each period. Logarithmic or square root 
transformation of the data was performed when necessary to obtain normally 
distributed data and when the data stayed skewed after transformation, 
nonparametric tests were applied. The Repeated measures followed by the 
Bonferroni method for pair-wise comparison was applied to assess differences 
among baseline, supplementation and follow-up periods in total number of cells 
and bacteria, numbers and percentages of Bacteroides/Prevotella, Eubacterium 
rectale/Clostridium coccoides group, Eubacterium low G+C2 and Ruminococcus 
group, and in ß-galactosidase activity and SSC. The Friedman test followed by a 
Wilcoxon test for pair-wise comparison was applied to assess differences among 
baseline, supplementation and follow-up periods in numbers and percentages of 
Bifidobacterium. The Student t-test (paired, two-tailed) was applied to assess 
differences in LDI before and after supplementation. Correlations were assessed by 








0.05 was regarded as significant. All analyses were performed using SPSS 12.0 for 





Effects of yogurt and bifidobacteria supplementation on the amount and 
composition of the colonic microbiota (Table 1) 
 
The numbers of total cells (P =0.05), total bacteria (P = 0.03) and the Eubacterium 
rectale/Clostridium coccoides group (P = 0.04) increased significantly during 
supplementation, but returned to the level of that in the baseline period after 
supplementation had stopped ( P > 0.1). The number of Bifdobacterium showed a 
tendency of increase in supplementation and follow-up periods, but this was not 
significant (P = 0.07). The percentages of Bacteroides/Prevotella, Eubacterium 
rectale/ Clostridium coccoides group, Eubacterium low G+C2, Ruminococcus 
group or Bifidobacterium (with total bacteria as 100%) were not different among 
baseline, supplementation or follow-up periods ( P > 0.1).  
 
Effects of yogurt and bifidobacteria supplementation on bifidobacterial 
population in faeces 
 
Dynamics in faecal bifidobacterial population was monitored with PCR-DGGE. As 
an example, Figure 2 shows the DGGE profile of four subjects. In the baseline 
period, no bands were present at the same level as the band from B. animalis in the 
yogurt in all faecal samples. In 10 of the 11 subjects, a band at the same level as the 
band from B. animalis appeared during supplementation, but disappeared again 
after supplementation had stopped. In six of the 11 subjects, a band at the same 
level as the band from B. longum in Bifina®capsules was already present in the 
baseline period and this did not change during or after supplementation. In others 
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present after supplementation, although in three of these samples the band appeared 
during supplementation. 
    The DGGE profiles of bifidobacteria showed host-specific patterns. Differences 
were found among subjects in the positions of specific bands and the number of 
bands. The profile of each subject in the follow-up period was similar to that in the 
baseline period except for some slight changes, e.g., in three subjects, new bands 
appeared during and after supplementation. 
    In two of the 11 subjects, no band at all was present in the baseline period. In 
one of them, two bands at the same levels as bands from the consumed B. animalis 
and B. longum appeared during supplementation but disappeared after 
supplementation. In another subject, besides two bands as B. animalis and B. 
longum, another band appeared during supplementation and while these three 
bands disappeared after supplementation, a new band appeared. 
Results of bifidobacteria measured with DGGE and FISH showed similar trends. 
Samples in which the numbers of bifidobacteria were below the detection limit of 
FISH had no band or just a few bands on DGGE profiles, while samples with 
bifidobacteria above the detection limit of FISH showed more bands on DGGE 
profiles. In some samples in which no bifidobacterium were detected with FISH, 
there were bands present on DGGE profiles (e.g. Figure 2, subject 1, sample 3). 
 
Effects of yogurt and bifidobacteria supplementation on faecal ß-galactosidase 
activity 
ß-galactosidase activity in faeces increased significantly during 
supplementation (P = 0.01; Table 2). In the follow-up period, ß-
galactosidase activity remained higher than that of baseline period, but the 
difference was not significant (P = 0.37). ß-galactosidase activity was not 
correlated with the total number of cells or bacteria, numbers of 
Bacteroides/Prevotella, Eubacterium rectale/ Clostridium coccoides group, 
Eubacterium low G+C2, Bifidobacterium (P > 0.1) or Ruminococcus group 
(P = 0.09). ß-galactosidase activity was not correlated with SSC (P > 0.1).
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Table 1. Numbers of total cells, total bacteria, and predominant bacterial groups in faeces of lactose intolerant subjects detected with FISH and DAPI staining 
before, during and after supplementation of the yogurt and Bifidobacterium longum1. 
 
  Baseline period  Supplementation period   Follow-up period 
Stain or probes Targeted groups Cells (1010) 2    %total bacteria3  Cells (1010) 2   %total bacteria3  Cells (1010) 2    %total bacteria3 
DAPI Total cells   14.5 ± 6.3    20.6 ± 4.9*    17.4 ± 8.5 
Eub338 Bacteria   12.9 ± 4.9    19.5 ± 5.5†    17.6 ± 7.9 
Bac303 Bacteroides/Prevotella   3.4 ± 1.7          27.7 ± 12.3    5.3 ± 2.9           26.5 ± 12.0    4.6 ± 3.3          27.1 ± 18.2 
Erec482 Eubacterium rectal  Clostridium coccoides group   2.5 ± 1.4          19.6 ± 7.1    4.2 ± 1.3
‡
          22.2 ± 6.9    3.3 ± 1.8          20.2 ± 9.0 
Elgc01 Eubacterium low G+C2   0.8 ± 0.5            6.4 ± 3.1    1.2 ± 0.6             6.1 ± 2.7    1.5 ± 0.8            8.9 ± 4.4 
Rbro729/Rfla730 Ruminococcus group   1.1 ± 1.1            7.7 ± 6.5    0.6 ± 0.5             3.6 ± 3.2    1.3 ± 0.7            8.6 ± 7.5 
Bif164y Bifidobacterium   0.1 ± 0.1            0.8 ± 1.0    0.2 ± 0.3             1.2 ± 1.4    0.3 ± 0.5            2.2 ± 3.6 
 
1
 Values are means ± SD or %, n=11 (baseline period and during) or 10 (after). 
2
 per g faeces, dry weight 
3 Percentage of Bacteria (Eub338). 
*
 P=0.052 compared to baseline period 
†
 P=0.026 compared to baseline period 
‡





Figure 2. PCR-DGGE analysis of bifidobacterial population in faeces of four lactose intolerant subjects before, during and after 
supplementation of the yogurt and Bifidobacterium longum. (A) Bifidobacterium animalis obtained from the yogurt, (L) Bifidobacterium 
longum obtained from Bifina® capsules, and (M) a mixture of 6 Bifidobacterium strains: (from top to bottom) B. adolescentis, B. dentum, B. 
breve, B. longum & B. pseudolongum and B. bifidum. For each subject, sample 1-2, 3-4 and 5 were from the baseline, supplementation and 
follow-up periods, respectively. Arrows indicate the presence of a band at the same level as the band from B. longum in the yogurt during 
the supplementation period. Numbers of Bifidobacterium (109 cells/g dry faeces) quantified with FISH are shown under the DGGE profile. 
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Effects of yogurt and bifidobacteria supplementation on digestion of lactose in 
the small intestine 
LDI was measured one day before and one day after the supplementation as an 
indication of the degree of lactose digestion in the small intestine. Supplementation 
of yogurt and bifidobacteria did not change LDI (P = 0.74; Table 2), which 
indicates that the endogenous (brush-border) small-intestinal lactase activity was 
not stimulated by the supplementation. 
 
Effects of yogurt and bifidobacteria supplementation on SSC 
SSC recorded in the follow-up period was significantly lower than that in the 
baseline period (P = 0.02; Table 2). Compared to the SSC obtained in the year 
previous to the study (18.3 ± 10.3, means ± SD, n=10), SSC in the baseline period 
was not different (P = 1.00). However, SSC in the follow-up period was 
significantly lower than that of the previous year (P = 0.01; Figure 3). 
 
Time










Figure 3. 6-h symptom scores (SSC) of individual lactose intolerant subjects recorded in 
the year previous to the study (n=10), and in the baseline and follow-up periods of the study 
(n=11). SSC in the baseline period was not different from that of the previous year (P = 
1.00). SSC in the follow-up period was significantly lower than those of the previous year
 (P = 0.01) and baseline period (P = 0.02).
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Table 2. Faecal ß-galactosidase activity, LDI and SSC of lactose intolerant subjects before, 
during and after supplementation of the yogurt and Bifidobacterium longum1. 
 
 Baseline period Supplementation period Follow-up period 
ß-galactosidase 
 (U/mg feces) 6.4 ± 6.3 10.6 ± 8.3
*
 8.9 ± 9.0 
LDI 0.39 ± 0.14 nm2 0.38 ± 0.20 
6 h SSC 16.1 ± 10.0 nm2 7.1 ± 5.5† 
         
1
 Values are means ± SD, n=11 
2 Not measured 
* P=0.01 compared to baseline period 






This study shows that a 2-w supplementation of probiotic bacteria Bifidobacterium 
longum and a yogurt enriched with Bifidobacterium animalis modifies the amount 
of bacteria and increases ß-galactosidase activity in faeces from lactose intolerant 
subjects. However, Bifidobacterium animalis does not colonize in the colon and 
composition of the faecal microbiota remains unchanged. The supplementation 
does not increase the brush-border lactase activity in the small intestine, however, 
SSC after the lactose challenge decreases after the supplementation. 
Yogurt and probiotic supplementation increased numbers of total cells, total 
bacteria and Eubacterium rectale/Clostridium coccoides group in faeces in this 
study. The increase in bacterial numbers could be attributed to, at least partly, the 
lactose present in the yogurt. During the production of yogurts, only 20~30% of the 
lactose is hydrolyzed in the fermentation process (12). The supplemented yogurt 
per day contained about 11.5 g lactose. Only ~40% of the ingested lactose (in water) 








Lactose in yogurt is better ingested, but not all lactose in yogurt can be digested in 
lactase-deficient subjects (33,34). Thus, during the supplementation period, up to 7 
g of lactose would enter the colon per day and serve as a substrate for fermentation 
by the colonic microbiota. Presence of lactose is expected to stimulate the bacterial 
ß-galactosidase activity. The Eubacterium rectale/Clostridium coccoides group has 
been shown to possess ß-galactosidase activity (35). In two other studies, yogurt 
supplementation did not result in an increase in the number of total anaerobes in 
healthy infants (20)or healthy German adults (18), which was probably caused by 
the fact that healthy infants and most German adults can digest lactose well. 
Supplementation of yogurt would thus not bring a considerable amount of lactose 
to their colon. In contrast to this, a study carried out in Chinese subjects in Taiwan 
(19) showed increased counts of anaerobes after yogurt ingestion. Most Chinese 
adults have genetically-determined low lactase activity (36). The above studies 
lend support to our assumption that maldigested lactose may serve as a substrate 
for the colonic microbiota and thus, will stimulate the growth of bacteria. 
Furthermore, the supplemented bifidobacteria, esp. B. animalis which was found to 
be present in the colon during the supplementation, may influence the colonic 
microbiota, considering their positive effects on intestinal ecology (18,37). 
Despite the change in the numbers of bacteria, the composition of the faecal 
microbiota was not changed by the supplementation. The stability of the colonic 
microbiota in healthy subjects (38) and during similar dietary supplementation as 
the present study (27,39) were reported earlier. 
Bifidobacterium in faeces from the 11 subjects was enumerated with FISH in the 
year previous to the study. The number (7.3 (8.7)×108 cells/ g dry faeces, mean 
(SD)) and the percentage of Bifidobacterium (0.7% of total bacteria) in these 
subjects were considerably lower than those in European subjects (6.0 (4.0)×109 
cells/ g dry faeces, 4.8% of total bacteria) (24). Bifidobacterium is generally 
believed to possess health-beneficial properties (40). Unfermented milks 
containing B. longum might be effective in reducing breath hydrogen response and 
symptoms from lactose malabsorption (41). Bifidobacterium animalis DN-173 010 
is shown to exhibit probiotic properties in the colon (37). Effects of 
supplementation of B. longum in capsules and a yogurt containing B. animalis on 
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the faecal bifidobacteial population were investigated with FISH and PCR-DGGE 
in this study. FISH analysis shows a trend of increase in numbers of bifidobacteria. 
PCR-DGGE analysis shows host-specific patterns of Bifidobacterium that were 
relatively stable. A strain(s) similar to the B. longum in Bifina® capsules was 
already present in the colon of some of the subjects before the supplementation. In 
other subjects that did not have this B. longum strain before the supplementation, 
the strain did not colonize the colon after the supplementation had ceased.   A 
strain(s) similar to the B. animalis strain in the supplemented yogurt was not 
present in any subject before the supplementation. It was transiently present in the 
colon during the supplementation, but disappeared after consumption had stopped. 
It has been reported that once the adult gut microbiota is established, the 
colonization with new strains is usually difficult and transient and sustained oral 
doses are required for their middle- and long-term maintenance (42). In most 
studies, supplemented probiotic strains did not colonize the intestine, as observed 
in the present study (43-45). Duez et al. detected Bifidobacterium animalis DN-173 
010 one week after its ingestion had stopped with a colony immunoblotting method 
(46). It is good to bear in mind the possibility that the study of faecal samples alone 
might not be sufficient in evaluating colonization by a probiotic strain. In one study, 
the administrated probiotic strain was detected in colonic biopsies after its 
disappearance from faeces (47). 
For detection of Bifidobacterium in faeces, PCR-DGGE is more sensitive than 
FISH in the present study. The detection limit of PCR-DGGE is lower than that of 
FISH. 
Faecal ß-galactosidase activity was increased during the supplementation period. 
One of our recent studies indicate that a major part of the colonic microbiota 
possess ß-galactosidase activity (35) and the abundance of ß-galactosidase is not 
involved in lactose intolerance (3). Therefore, the increase in faecal ß-galactosidase 
activity may not necessarily be related to the reduced SSC, but rather, could be an 
indication of altered metabolic activities of the colonic microbiota or presence of 
the administered probiotic bacteria in the colon. Probiotics are found to be able to 
modify colonic fermentation (48,49). Modification of colonic fermentation of 








galactosidase activity could not be correlated with the changes in the amount of the 
colonic microbiota. The reasons for this can be that firstly, changes in metabolic 
activities occur without changes in composition of bacteria and secondly, our FISH 
method is not sensitive enough to detect the changes in bacterial composition 
responsible for the enzymatic changes. The large variation in bacterial numbers 
among individuals might make it difficult to clarify the relationship. 
SSC was reduced after the supplementation. Hertzler et al. observed colonic 
adaptation to regular lactose ingestion and suggested that this adaptation reduces 
lactose intolerance symptoms (17). Changes in the amount and metabolic pattern of 
the colonic microbiota as observed in this study can be among those adaptive 
changes. Furthermore, yogurt and probiotics are generally regarded to be able to 
improve lactose digestion and alleviate symptoms of intolerance. In this study, SSC 
of the baseline period was not different from the SSC of the previous year, whereas 
SSC decreased significantly after the supplementation compared to the baseline 
values. This indicates that the supplementation of yogurt and bifidobacteria 
alleviates the symptoms of lactose intolerance. 
Yogurt can efficiently improve lactose digestion through providing active 
microbial ß-galactosidase and slowing gastrointestinal transit (6). However, 
consumption of yogurt or yogurt combined with probiotics cannot stimulate the 
endogenous (brush-border) lactase activity in the small intestine, as indicated by 
the study from Lerebours et al. (50) and the present study. The alleviation of 
intolerance symptoms observed in the follow-up period of this study is not caused 
by improvement in digestion of lactose in the small intestine. 
Colonic metablism of lactose has been suggested to play a role in lactose 
intolerance (1-3). In this study, alleviation of lactose intolerance is not caused by 
improved digestion of lactose in the small intestine. The changes in the colonic 
microbiota might be among the factors modified by the supplementation which 
lead to reduction of symptoms. Modulation of colonic metabolism through dietary 
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Background: We observed recently that colonic fermentation of lactose might be a 
major factor in the pathophysiology of lactose intolerance. Proteomic techniques 
could be helpful in interpreting the metabolic pathways of lactose in the colon. The 
objective of this study was to explore proteomic methodologies for studying 
bacterial metabolism of lactose that can be used for identification of proteins 
involved in the colonic lactose metabolism which are associated with the onset of 
intolerance symptoms. 
Materials and methods: Differential expression of cytoplasmic proteins of 
Bifidobacterium animalis, breve and longum grown on different carbohydrates 
(lactose, glucose, galactose) was analyzed with surface-enhanced laser desorption 
ionization - time of flight (SELDI-TOF) MS and sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). After fractionation by SDS-
PAGE, differentially-expressed proteins among different carbohydrates were 
identified with LC-MS/MS. 
Results: The three strains grown on the same carbohydrate or the same strain 
grown on glucose or lactose showed differences in SELDI-TOF MS protein 
profiles. Differences in protein expression were observed among B. breve grown 
on glucose, galactose or lactose as analyzed with SDS-PAGE. With LC-MS/MS, 
proteins related to Bifidobacterium were identified, which included enzymes for 
metabolism of lactose, glucose and galactose. 
Conclusions: The applied techniques can discern differences in protein expression 
of bacteria metabolizing different carbohydrates. These under-developing 
techniques can be promising in studying metabolism of lactose and other substrates 











Lactose intolerance refers to the gastrointestinal symptoms related to incomplete 
digestion of lactose by the small intestinal enzyme lactase. The adult-type lactase 
non-persistence occurring in a large part of the world population leads to lactose 
maldigestion, which in turn can , though not in all cases, lead to lactose intolerance. 
The pathophysiology of lactose intolerance is not well understood. We recently 
described that besides the small intestinal lactase activity and transit, fermentation 
of lactose by the colonic microbiota may play a role in lactose intolerance (1). 
Dietary supplementations, esp. probiotics, have been used to alleviate symptoms of 
lactose intolerance (2-4). These supplementations are expected to modify 
metabolism of lactose in the small and large intestine in such away that symptoms 
can be prevented or alleviated. We observed that supplementation of a yogurt and 
probiotic bifidobacteria could alter the amount and metabolic activity of the 
colonic microbiota and alleviate intolerant symptoms in lactose intolerant subjects 
(unpublished data). 
    The role of colonic microbiota in lactose intolerance can be studied on the levels 
of bacterial composition and metabolic activities. In our recent studies in which 
fecal bacteria were quantified with fluorescent in situ hybridization, we did not 
observe significant differences in the composition of the fecal microbiota between 
lactose tolerant and intolerant subjects (1), or between lactose intolerant subjects 
with mild symptoms or with diarrhea (5), possibly because of large inter-individual 
differences. Studies on colonic metabolism of lactose by the colonic microbiota 
may reveal useful information on the pathophysiology of lactose intolerance. 
Proteomics technology can be an appropriate approach to study bacterial 
metabolism of lactose. Study of differential protein expression of colonic bacteria 
grown on lactose and other carbohydrates as energy source will facilitate detection 
of proteins specifically involved in lactose degradation. Differential proteomic 
analysis of the colonic microbiota from lactose tolerant and intolerant subjects may 
help to unravel the complex network of the proteins involved in bacterial 
metabolism of lactose which are correlated to the onset of intolerant symptoms. 








lactose intolerance and can be used to evaluate the effects of dietary intervention 
designed to alleviate lactose intolerance. 
    In this study, we aimed to explore proteomic methodologies for differential 
proteome analysis of the bacterial lactose metabolism. The profiles of cytoplasmic 
proteins of bifidobacteria grown on different carbohydrates were studied with the 
SELDI-TOF MS Proteinchip technology and SDS-PAGE. LC-MS/MS was applied 
to identify the differences in protein expression among bifidobacteria grown on 
different carbohydrates as analyzed with SDS-PAGE . With high throughput 
capacity and limited material requirements, SELDI-TOF MS has been shown to be 
useful for studying differential protein expression in bacteria (6-8). SDS-PAGE is 
used to separate proteins based on differences in mass. It is less powerful in 
resolution than two--dimensional polyacrylamide gel electrophoresis (2D-PAGE),  
but is faster and easier to use. The colonic microbiota is very complex. 
Bifidobacteria are a predominant group of the colonic microbiota, accounting for 
~5% of the total bacteria (9), and are generally regarded as health-promoting (10). 
As a first approach, Bifidobacterium was chosen as a model bacterium for studying 
fermentation of lactose by the colonic microbiota.  
 
 
Materials and Methods 
 
Bacterial strains and growth condition 
 
Three Bifidobacterium strains were used in this study: Bifidobacterium animalis 
(DSM 20104) and Bifidobacterium breve (DSM 20213) were purchased from the 
German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, 
Germany), Bifidobacterium longum (NCC 2705) was kindly provided by the Nestlé 
Research Center (Lausanne, Switzerland). The bacteria were grown at 37 °C under 
anaerobic conditions. For defining a method for bacteria culturing and protein 
extraction with SELDI-TOF Proteinchip arrays, B. animalis, B. breve and B. 
longum were grown in mLAPT medium (11) with lactose or glucose as energy 
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carbohydrate. For identification of proteins with LC-MS/MS, B. breve was cultured 
in mLAPT medium with lactose, or glucose or galactose as energy source (20 g L-
1). Growth of bacteria was monitored spectrophotometrically at 492 nm. When the 
optical density (492 nm) of the cultures reached ~0.7 (~1.5 × 108 cells/ml) which is 
corresponding to the mid-exponential growth phase, cells were harvested by 
centrifugation at 16100 × g for 5 min. The pellet was suspended in 1 ml 100 
mmol/L Tris-HCl (pH 7.4) and the suspension was centrifuged at 16100 × g for 5 
min. This step was then repeated twice. The pellet of cells was stored at -20 °C 




The cells were suspended in 0.5 ml 100 mmol/L Tris-HCl (pH 7.4). The suspension 
was sonicated on ice (4 × 1 min with 15 s interval, at an amplitude setting of 24) 
with a Soniprep 150 ( Beun de Ronde BV, Abcoude, the Netherlands) followed by 
centrifugation (16100 × g, 10 min). The supernatant was stored at -80 °C until 
analysis. The protein concentration in the extracts was determined with the 
Bradford assay (Sigma, Saint Louis, USA). 
 
SELDI-TOF MS analysis of cytoplasmic proteins 
 
The protein extracts of bifidobacteria were analyzed using strong-anion-exchange 
(SAX2) ProteinChip® arrays which were imbedded in a 96-well bioprocessor 
(Ciphergen Biosystems, Inc., Fremont, USA). The SAX chip was chosen because it 
showed the best results in terms of peak number and reproducibility in pilot 
experiments. Each of the quadruple cultures for each bifidobacterial strain grown 
on each carbohydrate was analyzed on one spot on the arrays. The arrays were 
equilibrated in a binding buffer (100 mmol/L Tris HCl (pH 10)-0.05% (v/v) Triton 
X 100) on a shaker for 5 min. Subsequently, the protein extracts (~20 µg of protein) 
in the binding buffer (final volume: 200 µl) were applied on the arrays. The arrays 
were shaken for 45 min to allow binding. After the samples were removed, the 








air-dried and 0.5 µl of a saturated solution of sinapinic acid (Ciphergen Biosystems, 
Inc.) in 50% acetonitrile (v/v)-0.5% trifluoroacetic acid (v/v) was applied twice as 
matrix. The arrays were then analyzed with a SELDI-TOF mass spectrometer 
(Ciphergen Biosystems, Inc.). Before the analysis, the mass spectrometer was 
calibrated using the All-in-One protein mix (mass range: 12 kDa-147kDa) 
(Ciphergen Biosystems, Inc.). 
Differences in protein spectra were analyzed using proteinchip software 3.1 with 
the integrated Biomarker WizardTM cluster analysis software (Ciphergen 
Biosystems, Inc.) as described earlier (12). 
 
SDS-PAGE analysis of cytoplasmic proteins 
 
SELDI does not allow direct identification of the observed differences in protein 
expression. To obtain more information on the nature of the observed differences, 
we separated cytoplasmic samples of B.breve grown on glucose, galactose and 
lactose with SDS-PAGE and excised bands that showed clear differences in 
intensity for protein identification with LC-MS/MS. As B.breve showed the most 
differences in growth when grown on different carbohydrates, it was chosen for 
analysis with SDS-PAGE and LC-MS/MS. Proteins extracted as described above 
were precipitated in acetone before SDS-PAGE fractionation followed by in-gel 
digestion. The acetone precipitate was directly dissolved in sample buffer 
(NuPAGE®-Novex, Invitrogen, Carlsbad, CA, USA) according to the protocol of 
the manufacturer and applied to a 12% Bis-Tris gel with a MOPS buffer system. 
Protein separation occurred for 50 min at 200V and visualization of bands was 
performed overnight by Coomassie Brilliant Blue G-250 based staining (PageBlue 
Staining Solution, Fermentas). Bands were excised, cut into small pieces and stored 
at -20 ºC until further analysis. 
 
Identification of cytoplasmic proteins with LC-MS/MS 
  
Gel pieces were washed in ultra pure water and dehydrated in acetonitrile. In-gel 
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with 55 mM iodoacetamide (45 min at room temperature in the dark) were 
performed. Gel pieces were subsequently washed with ultra-pure water, 
50% acetonitrile and 100% acetonitrile.  0.1 µg trypsin in 50 mM ammonium 
bicarbonate was added and gel pieces were allowed to rehydrate on ice for 20 
minutes. Digestion was carried out overnight at 37 ºC and peptides were further 
extracted by shaking the gel pieces in 0.1% formic acid for 30 min. 
Separation of the resulting tryptic peptide mixtures was performed by nanoscale 
reversed-phase liquid chromatography tandem mass spectrometry (LC-MS/MS). 
The Agilent 1100 nanoflow/capillary LC system (Agilent, Palo Alto, CA, USA) 
was equipped with a trapping column (5 x 0.3 mm C18RP) (Dionex/LC Packings, 
Amsterdam, The Netherlands)  and a  nanocolumn (150 x 0.075 mm, C18Pepmap) 
(Dionex/LC Packings). Peptides mixtures were injected into the trapping column at 
a flow rate of 10 µl/min (5% acetonitrile/0.1% formic acid). After 10 minutes the 
trapping column was switched into the nanoflow system and the trapped peptides 
were separated using the nanocolumn at a flow rate of 0.25 µl/min in a linear 
gradient elution from 95% A (5% acetonitrile/0.1% formic acid) to 50% B (95% 
acetonitrile/0.1% formic acid) in 60 min, followed by an increase up to 80% B in 
5 min. The eluted peptides were on-line electrosprayed into the QStar XL Hybrid 
ESI Quadrupole time-of-flight tandem mass spectrometer, ESI-qQTOF-MS/MS 
(Applied Biosystems, Framingham, MA; MDSSciex, Concord, Ontario, Canada) 
provided with a nanospray source equipped with a New Objective ESI needle (10 
µm tip diameter). Typical values for needle voltage were 2 kV in positive ion mode. 
The mass spectrometer was set to perform data acquisition in the positive ion mode, 
typically with a selected mass range of 300-1400 m/z. Peptides with +2 to +4 
charge states were selected for tandem mass spectrometry, and the time of 
summation of MS/MS events was set to be 2 seconds. The three most abundant 
charged peptides above a 30 count threshold were selected for MS/MS and 
dynamically excluded for 60 seconds with 100 ppm mass tolerance. 
ProID software (Applied Biosystems) was used to identify proteins from the mass 
spectrometric datasets according to SwissProt database. Mass tolerance was set to 
0.15 Da (MS) and 0.1 Da (MS/MS) and carboxamidomethylation and methionine 










Influence of different carbohydrates on the growth of Bifidobacterium 
 
Based on the growth curves of the different bifidobacterial strains on the three 
carbohydrates, it can be noticed that the growth of B. animalis (DSM 20104) on 
glucose and lactose was similar (Fig. 1 A), whereas B. longum (NCC 2705) grew 
relatively better on lactose than on glucose (Fig. 1 B). B. breve (DSM 20213) 
showed the best growth on lactose, whereas its growth on glucose and galactose 
was similar (Fig. 1 C).  
 
 
Reproducibility of the protein profiles as analysed with SELDI-TOF MS 
 
Four cultures were inoculated for each stain grown on each carbohydrate. The 
quadruple cultures were harvested independently, cytoplasmic proteins extracted 
and applied to the proteinchips independently. The quadruple cultures showed 
similar spectra in terms of the number of peaks detected and the intensity of the 
peaks, with a few proteins of which peak intensity varied among replicates. Figure 
2 shows spectra of the quadruple cultures of B. breve grown on glucose as an 
example of this observation. Peaks with signal-to-noise ratio > 5 which were 
present in all these four spectra were identified with proteinchip software 3.1 with 
the integrated Biomarker WizardTM cluster analysis software (Ciphergen 
Biosystems, Inc.). For the 13 peaks identified, the average CV of the peak intensity 
































































Figure 1. Growth of Bifidobacterium animalis DSM 20104 (A), Bifidobacterium longum 
(NCC 2705) (B) and Bifidobacterium breve DSM 20213 (C) on different carbohydrates in 




















Figure 2. SELDI-TOF MS (WAX2 chips) spectra of cytoplasmic proteins (molecular 
weight range: 3000-20000 kDa) of the quadruple cultures of Bifidobacterium breve DSM 
20213 grown on glucose. The spectra peaks are transformed into a ‘gel view’ using the 




SELDI-TOF MS spectra of cytoplasmic proteins of B. animalis, B. breve and B. 
longum grown on different carbohydrates 
 
For the three strains, most peaks detected were in the molecular weight range of 1-
20 kDa. Only a few peaks were detected in the range of > 20 kDa (data not shown). 
Grown on the same carbohydrate, B. animalis, B. breve and B. longum showed 
considerable differences in protein expression (Fig. 3). Some peaks were detected 
in one strain but not in other two strains. Most of the peaks found in all three 
strains varied in intensity. One strain grown on different carbohydrates showed 
similar spectra. However, the intensity of certain peaks was significantly different 
among different carbohydrates (Table 1). All the differences showed in Table 1 
were significant and with  2-fold changes. When B. animalis was grown on 
lactose, the intensity of seven peaks increased and one decreased compared to that 
when grown on glucose. The intensity of two peaks, ~4757 Da and ~9275 Da, 
decreased in both B. breve and B. longum grown on glucose compared to on lactose. 
In B. breve, the intensity of three peaks increased when grown on glucose 
compared to on lactose. 
 
















Figure 3. SELDI-TOF MS (WAX2 chips) spectra of cytoplasmic proteins (molecular 
weight range: 3000-20000 kDa) of Bifidobacterium breve DSM 20213 grown on glucose(A) 
and lactose (B), Bifidobacterium animalis DSM 20104 grown on glucose(C) and lactose 
(D), Bifidobacterium longum (NCC 2705) grown on glucose (E) and lactose (F). Each 


















































Table 1. Differences in SELDI-TOF protein profiles of Bifidobacterium grown on glucose 
and lactose. The intensity of the peaks were significantly different between glucose and 
lactose with at least 2-fold differences in their intensity. 
 













3442,8 2,7  3410,9 3,9  4756,9 0.5 
3582,2 2,6  4204,0 2,2  9279,0 0.5 
5148,2 0,3  4757,4 0.5    
7787,6 2,5  8167,5 2,6    
8646,4 2,1  9274,6 0.5    
10232,3 3,1       
12388,3 2,0       





Table 2. Proteins identified in the band of B. breve grown on glucose in the rectangle in 
Figure 5. 
 
N Total ProtSc Accession Protein Name and Species 
1 13,9 Q8G3V9_BIFLO UDP-glucose 4-epimerase.- Bifidobacterium longum 
2 7,7 Q8G4T6_BIFLO Probable transcription antitermination protein.- Bifidobacterium 
longum 
3 7,7 Q8G510_BIFLO Hypothetical protein.- Bifidobacterium longum 
4 5,2 Q8G5M3_BIFLO Hypothetical protein.- Bifidobacterium longum 
5 4,8 1LTHT L-lactate dehydrogenase (EC 1.1.1.27) mutant (C199S) (mixed 
t- and r- state tetramers), chain T - Bi 
6 4,0 1AVWA trypsin (EC 3.4.21.4), chain A - pig 
7 3,8 AAF60327 AF237621 NID: - Homo sapiens 
8 2,8 Q9L4Z7_BIFLO L-lactate dehydrogenase (Fragment).- Bifidobacterium longum 
bv. Infantis 
9 2,0 CAA63080 SCRPOA NID: - Streptomyces coelicolor A3(2) 
10 2,0 Q8G5Z8_BIFLO Probable 50S ribosomal protein L25.- Bifidobacterium longum 
11 1,7 AAN25299 AE014295 NID: - Bifidobacterium longum NCC2705 
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SDS-PAGE analysis of cytoplasmic proteins and identification of differentially 
-expressed proteins with LC-MS/MS 
 
Differences existed in cytoplasmic proteins of B.breve grown on glucose, galactose 
and lactose as analyzed with SDS-PAGE (Fig. 4). The molecular weight of most of 
the differentially expressed proteins that could be discerned on the SDS-PAGE gel 
were above 28 kDa.  Bands showing different intensities among the three different 
carbohydrates were processed for protein identification by LC-MS/MS. In total, 8 
bands (indicated with arrows in Fig. 4) from each carbohydrate were excised, 
respectively. In the 8 bands from glucose, galactose and lactose, 78, 77 and 59 
proteins were identified, respectively (> 95% confidence). We present results of 
three bands from glucose, galactose and lactose which were excised from the 38 
kDa area (Fig. 4, in the rectangular) as an example of protein identification. More 
than one protein was identified in each of the three bands. As shown in Table 2, 12 
proteins were identified in the band from glucose (Fig. 4, lane B), nine of which 
were directly related to Bifidobacterium in the database search results. Three of 
these nine proteins are involved in carbohydrate metabolism. In Table 3, identified 
proteins in these three bands were grouped according to the carbohydrate lane 
where they have been detected. Of the proteins identified, some were present in all 





During bacterial fermentation of lactose, lactose is first hydrolyzed into glucose 
and galactose. ß-galactosidase is the enzyme that catalyzes this hydrolytic step. In 
recent studies, we observed that the degree and rate of this hydrolysis was not 
different between lactose tolerant and intolerant subjects, whereas the intolerant 
subjects had a higher and faster production of short-chain fatty acids and lactate (1). 
Hydrolysis of lactose may not be a rate-limiting step in lactose fermentation as 
bacterial ß-galactosidase activity is abundant in the colon (13). These observations 








itself, may be the crucial steps in lactose intolerance. Proteomic techniques can be 
helpful in studying metabolism of substrates by the colonic microbiota. In this 
study, we aimed to explore proteomic methodologies for differential proteomic 
analysis of lactose metabolism by the colonic bacteria. Understanding bacterial 
metabolism of lactose would help to clarify the possible role of colonic metabolism 
in lactose intolerance. 
The major metabolic pathways for glucose, galactose and lactose are similar as 
lactose is first hydrolyzed to glucose and galactose, galactose is subsequently 
transformed to glucose (14,15). Therefore, differential proteomic analysis of 
bacteria grown on these carbohydrates provides a good model system for 
identification of proteins specifically involved in lactose degradation and for 
developing proteomic techniques which are expected to discern subtle changes in 
protein expression profiles. 
In a pilot study, a stool sample was cleaned with 24% Polyethylene Glycol and 
33% Dextran. Cytoplasmic proteins obtained by sonication were applied on 
SELDI-TOF MS Proteinchips. However, no useful spectra could be obtained, 
suggesting that stool samples are too complex in their protein composition and 
need extensive pre-treatment before they can be used for proteomic analysis (data 
not shown). In this study, a model system of Bifidobacterium was chosen for 
studying fermentation of lactose by the colonic microbiota. We have chosen 
Bifidobacterium because of its claimed health-promoting effects and the 
knowledge of its genome. The genome of B. longum strain NCC2705 was 
sequenced in 2002 (16). Recently, a comprehensive proteomic study was carried 
out to identify and characterize proteins expressed by the same strain (17). 
Currently, 2D-PAGE is the technique extensively used in proteomic studies. 2D-
PAGE can be a choice as a methodology for identification of proteins involved in 
lactose metabolism. However, considering its time-consuming procedure and 
difficulties in resolving some proteins, such as proteins with extreme pI and Mr 
(18), other approaches were explored for our purposes. We chose the SELDI-TOF 
MS Proteinchip array and SDS-PAGE for differential analysis of Bifidobacterium 
grown on different carbohydrates. SELDI-TOF MS has certain advantages over 












Figure 4. SDS-SDS-PAGE analysis of cytoplasmic proteins of Bifidobacterium breve 
DSM 20213 grown on (A) glucose, (B) galactose and (C) lactose. (M), markers for 
molecular weight of proteins. The arrows indicate the positions of the 8 bands from each 
sugar which were excised. The three bands in the rectangle are examples of the bands of 
which the intensity was different among the three carbohydrates and which were excised 








Table 3. Proteins identified in the three bands of B. breve grown on glucose, galactose and 
lactose in the rectangle in Figure 5. 
 




 UDP-glucose 4-epimerase.- Bifidobacterium longum 
 Hypothetical protein.- Bifidobacterium longum 
 AE014295 NID: - Bifidobacterium longum NCC2705 
Galactose & 
Glucose 
 Probable transcription antitermination protein.- Bifidobacterium longum 
 Hypothetical protein.- Bifidobacterium longum 
 L-lactate dehydrogenase (Fragment).- Bifidobacterium longum bv. infantis 




 Transaldolase.- Bifidobacterium longum 
 DTDP-glucose 4,6-dehydratase enzyme involved in rhamnose biosynthesis.- 
Bifidobacterium longum 
Galactose   (12 proteins), e. g.: Cystathionine beta-synthase.- Bifidobacterium longum 
 Aspartate-semialdehyde dehydrogenase.- Bifidobacterium longum 
 Glyceraldehyde 3-phosphate dehydrogenase C.- Bifidobacterium longum 
Glucose   L-lactate dehydrogenase (EC 1.1.1.27) mutant (C199S) (mixed t- and r- state 
tetramers), chain T – Bi 
 Probable 50S ribosomal protein L25.- Bifidobacterium longum 
Lactose   L-lactate dehydrogenase (EC 1.1.1.27) - Bifidobacterium longum 
 L-lactate dehydrogenase (Fragment).- Bifidobacterium longum bv. Infantis 





This technique has higher throughput capability, has subfemtomole range 
sensitivity, offers higher resolution at the low mass range (i.e. <20kDa), and is 
relatively easy to use (19,20). In our study, with SELDI-TOF MS, differences in 
protein expression of different bifidobacterial strains and one bifidobacterial strain 
on different sugars could be detected in the low molecular weight range (<20kDa). 
The measurement with SELDI-TOF-MS in our experimental setting was 
reproducible. Therefore, SELDI-TOF MS can be used as a complementary 
approach to 2D-PAGE or SDS-PAGE in detecting peptides and proteins of low 
molecular weight (<20kDa) involved in lactose metabolism from defined bacterial 
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high throughput, it can be used for screening of sample quality and for optimization 
of techniques, for instance, culturing of bacteria and sample preparation. 
      In addition to SELDI-TOF MS, we also used SDS-PAGE for differential 
analysis of bifidobacterial proteins in a wider mass range, esp. the higher mass 
range (>20kDa). Differences were detected in protein expression of B. breve grown 
on glucose, galactose or lactose. With LC-MS/MS, proteins that were possibly 
responsible for these differences were identified. Most of the proteins were related 
to Bifidobacterium, including enzymes for metabolism of certain sugars. However, 
as one band on the SDS-PAGE gel contained more than one protein and analysis 
with LC-MS/MS was not quantitative, differences in protein expression could not 
be directly related to certain proteins. 2D-PAGE would probably be helpful in 
discriminating which of these proteins are differentially expressed. 
For future studies on lactose metabolism by the colonic microbiota with 
proteomic techniques, we propose the following strategy: labeling of bifidobacteria 
grown on different carbohydrates with stable isotopes, followed by fractionation by 
SDS-PAGE and finally identification by LC-MS/MS. With the stable isotope 
labeling technique (21,22), proteins can be identified in a quantitative manner, 
which will facilitate identification of proteins of which expression is induced by 
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The research protocol for an in vivo study on colonic 










We recently observed in vitro that a faster and higher production of microbial 
intermediate and end metabolites during colonic fermentation of lactose may be 
related to the onset of lactose-induced symptoms. In vitro systems may not be a 
perfect reflection of the in vivo situation. In vivo studies are needed to verify the in 




To investigate in vivo whether fermentation of lactose by the colonic microbiota 




13C-lactose and  2H-acetate will be delivered quantitatively via a catheter to the 
colon. 2H-acetate serves as an internal reference for the absorption rate of the colon 
and the Splanchnic first-pass retention of acetate. The kinetics of 13C-acetate in 




1.      Classification of lactose tolerant (n=6) and intolerant subjects (n=6) 
1.1    ~30 Chinese subjects will undergo one glucose (placebo control) and one 
lactose challenge in two single-blinded tests. A 6-h symptom score will be 
recorded and breath samples will be collected for measurement of hydrogen. 
1.2    Criteria for classification: (i) breath hydrogen test positive; (ii) no symptoms 
after glucose, (iii) tolerant: no symptoms after lactose, intolerant: symptoms after 
lactose. 
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3.      Introduction of substrates via the catheter 
3.1    Substrates: 500 mg 13C-lactose + 19.5 g lactose + 200 mg 2H-acetate, 
                            dissolved in 204 ml of sterile water (37°C) 
3.2     Infusion rate: 4.5 ml/min 
 
4.      Collection of samples 
4.1     Blood: from an antecubital vein, 6 ml every 15 min from -45 min till 240 
min 
4.2     Breath: every 15 min from -45 min till 240 min 
4.3     Stool: 24 h stool after infusion starts 
 
5.      Measurement 
5.1  Plasma: 13C-acetate (Gas chromatography/combustion/ isotope ratio mass 
spectrometry, GC-/C/IRMS) and 2H-acetate (GC-MS) 
5.2    Breath: 13C-CO2 (GC/C/IRMS) 
5.3    Stool: 13C-enrichment 
 
6.      Data analysis 
6.1    Calculate ratio 13C / 2H-acetate 
6.2    Compare production rate of 13C-acetate (with ratio 13C / 2H-acetate) between 
lactose tolerant and intolerant subjects 












Zuivelprodukten zijn voor ons een bron van calcium en andere waardevolle 
voedingsstoffen. Ze bevatten echter ook lactose en dat wordt niet goed verteerd 
door een groot deel van de volwassen wereldbevolking. Hoe de slechte vertering 
van lactose leidt tot symptomen van lactose-intolerantie is niet geheel duidelijk. 
Mogelijk kunnen pathofysiologische onderzoeken helpen om strategieën te 
ontwikkelen om lactose-intolerantie via dieetaanpassing te verminderen. Er zijn 
enige aanwijzingen dat het lactose-metabolisme in de dikke darm samen met de 
lactase-activiteit en de passage in de dunne darm een rol speelt bij het ontstaan van 
de symptomen van intolerantie. 
      Er zijn gegevens nodig over de vertering en de passage van lactose in de dunne 
darm als we de mogelijke rol van de dikke darm in lactose-intolerantie willen 
verklaren. De duur van de passage van de mond tot het begin van de dikke darm: 
de oro-cecal transit time (OCTT), en de mate van lactose-vertering werden bepaald 
met recent ontwikkelde methoden waarbij gebruik gemaakt werd van stabiele 
isotopen. Lactose veroorzaakte een snellere oro-cecal transit in personen die 
lactose slecht konden verteren. In personen die lactose goed konden verteren was 
dit niet het geval. Dit kon niet worden verklaard door uitzetting van de darm door 
een osmotisch effect ten gevolge van de niet-verteerde lactose. Lactose zou daarom 
een direkt effect kunnen hebben op intrinsieke factoren die de darmmotiliteit 
reguleren. De OCTT en de mate van lactose-vertering waren gelijk in lactose-
intolerante en –tolerante personen. Dit duidt er op dat andere mechanismen een rol 
spelen bij lactose-intolerantie. Onze hypothese is dat het  lactose-metabolisme in de 
dikke darm een van deze mechanismen is.  
      Er zijn twee in vitro onderzoeken verricht naar de rol die fermentatie van 
lactose door bacteriën in de dikke darm zou kunnen spelen in lactose-intolerantie. 
Tijdens deze fermentatie wordt lactose gesplitst in glucose en galactose. Deze 
hydrolyse wordt gekatalyseerd door -galactosidase. Glucose en galactose worden 
verder gefermenteerd met als eindproducten korte-keten vetzuren en gassen. In 
vitro incubatie van lactose met bacteriën uit feces afkomstig van lactose-intolerante
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personen leverde sneller en meer lactaat, acetaat, propionaat en butyraat dan 
incubatie met feces-bacteriën van lactose-tolerante personen. De snellere en grotere 
productie van microbiële tussen- en eindproducten tijdens de fermentatie in de 
dikke darm zou gerelateerd kunnen zijn aan het onstaan van de symptomen van 
lactose-intolerantie. Het is niet waarschijnlijk dat de mate en snelheid van lactose-
hydrolyse hierbij van belang zijn. In de dikke darm is -galactosidase-activiteit 
rijkelijk aanwezig, aangezien meer dan 80% van de gekweekte feces-bacteriën 
deze activiteit bevatten. De relatieve hoeveelheid en de samenstelling van feces-
bacteriën met -galactosidase-activiteit verschilde niet tussen lactose-intolerante en 
–tolerante personen. Onze hypothese is dat accumulatie van korte-keten vetzuren 
en/of andere metabolieten die geproduceerd worden door de snelle fermentatie van 
lactose naast onvoldoende verwijdering van deze stoffen een rol speelt bij de 
ontwikkeling van symptomen.  
      Omdat het in vitro onderzoek aangaf dat fermentatie in de dikke darm van 
belang zou kunnen zijn bij lactose-intolerantie, werd vervolgens de aandacht 
gericht op de vragen: (i) of de bacteriële samenstelling in de dikke darm 
gemoduleerd kan worden door toevoegingen aan het dieet met als doel 
vermindering van de symptomen; (ii) of  met proteomics meer duidelijkheid over 
de fermentatie van lactose door de microbiota in de dikke darm  verkregen zou 
kunnen worden, en (iii) of de in vitro resultaten bevestigd kunnen worden door in 
vivo onderzoek. 
      Inname gedurende 2 weken van probiotische bacteriën (Bifidobacterium 
longum) en een yoghurt verrijkt met Bifidobacterium animalis modificeerden de 
hoeveelheid en waarschijnlijk ook de metabole activiteit van de bacteriën in de 
dikke darm van lactose-intolerante personen. Door lactose geïnduceerde 
symptomen verminderden na deze inname. De toevoeging had geen effect op de 
endogene lactase-activiteit in de dunne darm. Deze resultaten  geven aan dat 
veranderingen in de bacteriële samenstelling in de dikke darm  een rol zouden 
kunnen spelen in vermindering van de intolerantie-symptomen. 
      Bifidobacteriën werden gebruikt als modelsysteem om proteomics methoden te 
exploreren. Deze methoden kunnen toegepast om te bestuderen op welke manier 








eiwitexpressie-profielen van Bifidobacterium gegroeid op lactose, glucose of 
galactose werden verkregen met surface-enhanced laser desorption ionization – 
time of flight MS en natriumdodecylsulfaat-polyacrylamidegelelektroforese. LC-
MS/MS werd gebruikt voor de identificatie van eiwitten. 
      Er wordt een voorstel voor een  in vivo onderzoek beschreven dat de 
waarneming uit het in vitro onderzoek zou kunnen bevestigen dat snelle 
fermentatie van lactose in de dikke darm een rol speelt in lactose-intolerantie. 
Lactose gelabeld met 13C  zal via een catheter in het coecum worden gebracht en 
vervolgens zal de kinetiek van de metaboliet 13C-acetaat in het perifere bloed 
worden gevolgd. 
      De resultaten gepresenteerd in deze dissertatie dragen bij aan het begrijpen van 
het lactose-metabolisme in de dikke darm in de context van lactose-intolerantie. 
Fermentatie van lactose in de dikke darm zou een rol kunnen spelen in lactose-
intolerantie. Moduleren van de bacteriële samenstelling in de dikke darm door het 
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